| Year |
Citation |
Score |
| 2021 |
Zhou Q, Xu CR, Cheng Y, Liu YP, Chen GY, Cui JW, Yang N, Song Y, Li XL, Lu S, Zhou JY, Ma ZY, Yu SY, Huang C, Shu YQ, ... ... Wu YL, et al. Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study. Cancer Cell. PMID 34388377 DOI: 10.1016/j.ccell.2021.07.005 |
0.331 |
|
| 2021 |
Passaro A, de Marinis F, Tu HY, Laktionov KK, Feng J, Poltoratskiy A, Zhao J, Tan EH, Gottfried M, Lee V, Kowalski D, Yang CT, Srinivasa BJ, Clementi L, Jalikop T, ... ... Wu YL, et al. Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies. Frontiers in Oncology. 11: 709877. PMID 34307179 DOI: 10.3389/fonc.2021.709877 |
0.397 |
|
| 2021 |
Tu HY, Li YS, Yang JJ, Chen HJ, Jiang BY, Zhong WZ, Yang XN, Wu YL. Long-Term Survival of Over 6 Years with Afatinib Sequential Treatment in a Patient with EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Case Report. Clinical Drug Investigation. PMID 33861418 DOI: 10.1007/s40261-021-01025-6 |
0.351 |
|
| 2021 |
Ni J, Huang M, Zhang L, Wu N, Bai CX, Chen LA, Liang J, Liu Q, Wang J, Wu YL, Zhang FC, Zhang SY, Chen C, Chen J, Fang WT, et al. Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer. Thoracic Cancer. PMID 33787090 DOI: 10.1111/1759-7714.13942 |
0.316 |
|
| 2021 |
Wu YL, Smit EF, Bauer TM. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies. Cancer Treatment Reviews. 95: 102173. PMID 33740553 DOI: 10.1016/j.ctrv.2021.102173 |
0.395 |
|
| 2021 |
Tang WF, Wu M, Bao H, Xu Y, Lin JS, Liang Y, Zhang Y, Su J, Zhang JT, Xu FP, Chen JH, Fu R, Chen Y, Yang T, Chen QK, ... ... Wu YL, et al. Timing and origins of local and distant metastases in lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 33722707 DOI: 10.1016/j.jtho.2021.02.023 |
0.303 |
|
| 2021 |
Cheng Y, Mok TS, Zhou X, Lu S, Zhou Q, Zhou J, Du Y, Yu P, Liu X, Hu C, Lu Y, Zhang Y, Lee KH, Nakagawa K, Linke R, ... ... Wu YL, et al. Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050). Lung Cancer (Amsterdam, Netherlands). 154: 176-185. PMID 33721611 DOI: 10.1016/j.lungcan.2021.02.025 |
0.343 |
|
| 2021 |
Zhang L, Lu S, Cheng Y, Hu Z, Wu YL, Chen Z, Chen G, Liu X, Yang J, Zhang L, Chen J, Huang M, Tao M, Cheng G, Huang C, et al. Docetaxel maintenance therapy versus best supportive care after first-line chemotherapy with different dose docetaxel plus cisplatin for advanced non-small cell lung cancer (TFINE study, CTONG-0904): an open-label, randomized, phase III trial. Annals of Translational Medicine. 9: 338. PMID 33708965 DOI: 10.21037/atm-20-8078 |
0.322 |
|
| 2021 |
Kok PS, Lee K, Lord S, Yang JC, Rosell R, Goto K, John T, Wu YL, Mok TSK, Lee CK. Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis. Lung Cancer (Amsterdam, Netherlands). 154: 113-117. PMID 33647577 DOI: 10.1016/j.lungcan.2021.02.027 |
0.342 |
|
| 2021 |
Herbst RS, Wu YL, Tsuboi M. Osimertinib in EGFR-Mutated Lung Cancer. Reply. The New England Journal of Medicine. 384: 675-676. PMID 33596365 DOI: 10.1056/NEJMc2033951 |
0.35 |
|
| 2021 |
Xu C, Tu H, Sun Y, Li Y, Xu B, Wang B, Chen H, Wang Z, Zhou Q, Yang J, Yang Q, Wu Y. Adverse events in non-small cell lung cancer patients receiving immune checkpoint inhibitors: A single center, real-world study in China. Journal of Clinical Oncology. 39: e21081-e21081. DOI: 10.1200/JCO.2021.39.15_SUPPL.E21081 |
0.31 |
|
| 2021 |
Wu Y, Zhang L, Kim D, Liu X, Lee DH, Yang JC, Ahn M, Vansteenkiste JF, Su W, Felip E, Carbini M, Glaser S, Tanriverdi O, Chassot-Agostinho A, Tan DS. Phase 1b/2 study of capmatinib plus gefitinib in patients with EGFR-mutated, MET-dysregulated non-small cell lung cancer who received prior therapy: Final overall survival and safety. Journal of Clinical Oncology. 39: 9048-9048. DOI: 10.1200/JCO.2021.39.15_SUPPL.9048 |
0.321 |
|
| 2021 |
Shen B, Wu Y, Shi L, Feng J. P48.24 Anlotinib Combined with Etoposide as Maintenance Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Journal of Thoracic Oncology. 16: S509-S510. DOI: 10.1016/J.JTHO.2021.01.894 |
0.322 |
|
| 2020 |
Li XT, Zhang JT, Yan HH, Su J, Cheng ML, Sun QH, Zhong WZ, Wu YL, Zhang DX, Hou DJ. Gene co-expression modules integrated with immunoscore predicts survival of non-small cell lung cancer. Cancer Treatment and Research Communications. 26: 100297. PMID 33385734 DOI: 10.1016/j.ctarc.2020.100297 |
0.325 |
|
| 2020 |
Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Chawla A, Rosell R, Corral J, Migliorino MR, Pluzanski A, Noonan K, Tang Y, Pastel M, Wilner KD, ... Wu YL, et al. Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. Drugs. PMID 33331989 DOI: 10.1007/s40265-020-01441-6 |
0.404 |
|
| 2020 |
Tu HY, Wu YL. Effect of Dose Adjustments on the Safety and Efficacy of Afatinib in Chinese Patients with Mutated Non-Small Cell Lung Cancer Who Participated in the LUX-Lung Clinical Trial Program. Oncotargets and Therapy. 13: 12539-12547. PMID 33324072 DOI: 10.2147/OTT.S273866 |
0.374 |
|
| 2020 |
Lu S, Wang J, Cheng Y, Mok T, Chang J, Zhang L, Feng J, Tu HY, Wu L, Zhang Y, Luft A, Zhou JY, Ma Z, Lu Y, Hu C, ... ... Wu YL, et al. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078). Lung Cancer (Amsterdam, Netherlands). 152: 7-14. PMID 33321441 DOI: 10.1016/j.lungcan.2020.11.013 |
0.343 |
|
| 2020 |
Li XM, Li WF, Lin JT, Yan HH, Tu HY, Chen HJ, Wang BC, Wang Z, Zhou Q, Zhang XC, Su J, Chen RL, Wu YL, Yang JJ. Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901). Clinical Lung Cancer. PMID 33317922 DOI: 10.1016/j.cllc.2020.11.001 |
0.39 |
|
| 2020 |
Wu YL, Shi Y, Tan DSW, Xiaoqing L, Cheng Y, Zhou J, An TT, Lu Y, Zhu B, Bai C, Passos VQ, Lau YY, Xun L, Zhang L. Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6. Lung Cancer (Amsterdam, Netherlands). 150: 240-246. PMID 33249379 DOI: 10.1016/j.lungcan.2020.10.024 |
0.372 |
|
| 2020 |
Zhou Q, Chen M, Wu G, Chang JH, Jiang O, Cui JW, Han G, Lin Q, Fang J, Chen GY, Wu YL. GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. Translational Lung Cancer Research. 9: 2008-2015. PMID 33209620 DOI: 10.21037/tlcr-20-608 |
0.339 |
|
| 2020 |
Gao X, Wei XW, Zheng MY, Chen ZH, Zhang XC, Zhong WZ, Yang JJ, Wu YL, Zhou Q. Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer. Journal of Thoracic Disease. 12: 5822-5832. PMID 33209414 DOI: 10.21037/jtd-20-1630 |
0.38 |
|
| 2020 |
Zheng MM, Li YS, Tu HY, Jiang BY, Yang JJ, Zhou Q, Xu CR, Yang XR, Wu YL. Genotyping of cerebrospinal fluid associated with osimertinib response and resistance for leptomeningeal metastases in EGFR-mutated non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 33122107 DOI: 10.1016/j.jtho.2020.10.008 |
0.358 |
|
| 2020 |
Yang JJ, Fang J, Shu YQ, Chang JH, Chen GY, He JX, Li W, Liu XQ, Yang N, Zhou C, Huang JA, Frigault MM, Hartmaier R, Ahmed GF, Egile C, ... ... Wu YL, et al. A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer. Investigational New Drugs. PMID 33052556 DOI: 10.1007/s10637-020-01010-4 |
0.339 |
|
| 2020 |
Guo LH, Zhang MF, Zhang HL, Zhou JY, Cai XH, Long Y, Guo QS, Yang N, Zhao J, Xie ZH, Jiang B, Zhu Y, Fan Y, Xie CY, Hu Y, ... ... Wu YL, et al. Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma. Frontiers in Oncology. 10: 1568. PMID 33042801 DOI: 10.3389/fonc.2020.01568 |
0.315 |
|
| 2020 |
Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, et al. Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer. The New England Journal of Medicine. PMID 32955177 DOI: 10.1056/NEJMoa2027071 |
0.369 |
|
| 2020 |
Tu HY, Wu YL. Afatinib for the first-line treatment of mutation-positive NSCLC in China: a review of clinical data. Future Oncology (London, England). PMID 32927981 DOI: 10.2217/fon-2020-0320 |
0.331 |
|
| 2020 |
Duan J, Xu J, Wang Z, Bai H, Cheng Y, An T, Gao H, Wang K, Zhou Q, Hu Y, Song Y, Ding C, Peng F, Liang L, Hu Y, ... ... Wu YL, et al. Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal circulating tumor DNA Monitoring in Advanced EGFR-mutant Lung Adenocarcinoma under Gefitinib Treatment. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 32916309 DOI: 10.1016/j.jtho.2020.08.020 |
0.304 |
|
| 2020 |
Chen JH, Chu XP, Zhang JT, Nie Q, Tang WF, Su J, Yan HH, Zheng HP, Chen ZX, Chen X, Song MM, Yi X, Li PS, Guan YF, Li G, ... ... Wu YL, et al. Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patients. Thoracic Cancer. PMID 32633046 DOI: 10.1111/1759-7714.13542 |
0.351 |
|
| 2020 |
Liu SY, Sun H, Zhou JY, Jie GL, Xie Z, Shao Y, Zhang X, Ye JY, Chen CX, Zhang XC, Zhou Q, Yang JJ, Wu YL. Clinical characteristics and prognostic value of the mutation in Chinese non-small cell lung cancer patients. Biomarker Research. 8: 22. PMID 32607238 DOI: 10.1186/s40364-020-00199-z |
0.377 |
|
| 2020 |
Wu YL, Cheng Y, Zhou J, Lu S, Zhang Y, Zhao J, Kim DW, Soo RA, Kim SW, Pan H, Chen YM, Chian CF, Liu X, Tan DSW, Bruns R, et al. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. The Lancet. Respiratory Medicine. PMID 32479794 DOI: 10.1016/S2213-2600(20)30154-5 |
0.377 |
|
| 2020 |
Lu C, Dong XR, Zhao J, Zhang XC, Chen HJ, Zhou Q, Tu HY, Ai XH, Chen XF, An GL, Bai J, Shan JL, Wang YN, Yang SY, Liu X, ... ... Wu YL, et al. Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study. Journal of Hematology & Oncology. 13: 37. PMID 32295619 DOI: 10.1186/s13045-020-00866-6 |
0.365 |
|
| 2020 |
Wei XW, Gao X, Zhang XC, Yang JJ, Chen ZH, Wu YL, Zhou Q. Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer. Thoracic Cancer. PMID 32291971 DOI: 10.1111/1759-7714.13419 |
0.309 |
|
| 2020 |
Zhou JY, Liu SY, Wu YL. Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer. Expert Opinion On Drug Safety. PMID 32267188 DOI: 10.1080/14740338.2020.1753697 |
0.384 |
|
| 2020 |
Xu ST, Yin JC, Xi JJ, Wang Q, Zhong WZ, Wu YL. Treatment failure patterns of adjuvant gefitinib therapy and minimal residual disease detection in resected EGFR-mutant non-small cell lung cancer: author's reply. Translational Lung Cancer Research. 9: 160-162. PMID 32206565 DOI: 10.21037/tlcr.2019.11.14 |
0.323 |
|
| 2020 |
Arai S, Takeuchi S, Fukuda K, Taniguchi H, Nishiyama A, Tanimoto A, Satouchi M, Yamashita K, Ohtsubo K, Nanjo S, Kumagai T, Katayama R, Nishio M, Zheng MM, Wu YL, et al. Osimertinib overcomes alectinib resistance caused by amphiregulin in a leptomeningeal carcinomatosis model of ALK-rearranged lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31972351 DOI: 10.1016/j.jtho.2020.01.001 |
0.319 |
|
| 2020 |
Peng XX, Yu RY, Wu X, Wu SY, Pi C, Chen ZH, Zhang XC, Gao CY, Shao YW, Liu L, Wu YL, Zhou Q. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in wild-type advanced non-small cell lung cancer. Journal For Immunotherapy of Cancer. 8. PMID 31959728 DOI: 10.1136/jitc-2019-000376 |
0.341 |
|
| 2020 |
Xu C, Tu H, Sun Y, Li Y, Xu B, Wang B, Chen H, Wang Z, Zhou Q, Yang J, Wu Y. Safety of nivolumab/pembrolizumab in hepatitis B surface antigen-positive non-small cell lung cancer (NSCLC) patients. Journal of Clinical Oncology. 38: e21670-e21670. DOI: 10.1200/jco.2020.38.15_suppl.e21670 |
0.312 |
|
| 2020 |
Gray JE, Han J, Telaranta-Keerie A, Huang X, Kohlmann A, Hodge R, Rukazenkov Y, Chmielecki J, Espenschied CR, Wu Y, Ramalingam SS, Barrett JC, Odegaard JI. Clinical performance of a comprehensive novel liquid biopsy test for identifying non-small cell lung cancer (NSCLC) patients for treatment with osimertinib. Journal of Clinical Oncology. 38: 9553-9553. DOI: 10.1200/Jco.2020.38.15_Suppl.9553 |
0.331 |
|
| 2020 |
Shen B, Wu Y, Shi L, Feng J. 1795P Anlotinib combined with etoposide as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC): A single-arm, prospective phase II study Annals of Oncology. 31: S1040. DOI: 10.1016/j.annonc.2020.08.1556 |
0.305 |
|
| 2019 |
Papadimitrakopoulou VA, Han JY, Ahn MJ, Ramalingam SS, Delmonte A, Hsia TC, Laskin J, Kim SW, He Y, Tsai CM, Hida T, Maemondo M, Kato T, Jenkins S, Patel S, ... ... Wu YL, et al. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer. Cancer. PMID 31769875 DOI: 10.1002/Cncr.32503 |
0.359 |
|
| 2019 |
Zhang JT, Liu SY, Yan HH, Wu YL, Nie Q, Zhong WZ. Recursive partitioning analysis of patients with oligometastatic non-small cell lung cancer: a retrospective study. Bmc Cancer. 19: 1051. PMID 31694572 DOI: 10.1186/s12885-019-6216-x |
0.362 |
|
| 2019 |
Wang Z, Yang JJ, Tu HY, Yan HH, Wu YL. Retrospective study on bevacizumab in the treatment of non-small cell lung cancer with brain metastases. International Journal of Clinical Oncology. PMID 31587134 DOI: 10.1007/s10147-019-01552-5 |
0.312 |
|
| 2019 |
Nosaki K, Saka H, Hosomi Y, Baas P, de Castro G, Reck M, Wu YL, Brahmer JR, Felip E, Sawada T, Noguchi K, Han SR, Piperdi B, Kush DA, Lopes G. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer (Amsterdam, Netherlands). 135: 188-195. PMID 31446994 DOI: 10.1016/j.lungcan.2019.07.004 |
0.332 |
|
| 2019 |
Marinis F, Wu YL, de Castro G, Chang GC, Chen YM, Cho BC, Freitas HC, Jiang L, Kim SW, Martin C, Metro G, Provencio M, Vansteenkiste J, Vicente D, Zhou Q, et al. ASTRIS: a global real-world study of osimertinib in >3000 patients with T790M positive non-small-cell lung cancer. Future Oncology (London, England). PMID 31339357 DOI: 10.2217/fon-2019-0324 |
0.351 |
|
| 2019 |
Zhang YC, Zhou Q, Wu YL. Clinical management of third-generation EGFR inhibitor-resistant patients with advanced non-small cell lung cancer: current status and future perspectives. Cancer Letters. PMID 31201840 DOI: 10.1016/j.canlet.2019.05.044 |
0.331 |
|
| 2019 |
Schuler M, Paz-Ares L, Sequist LV, Hirsh V, Lee KH, Wu YL, Lu S, Zhou C, Feng J, Ellis SH, Samuelsen CH, Tang W, Märten A, Ehrnrooth E, Park K, et al. First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. Lung Cancer (Amsterdam, Netherlands). 133: 10-19. PMID 31200814 DOI: 10.1016/j.lungcan.2019.04.006 |
0.361 |
|
| 2019 |
Zhong WZ, Chen KN, Chen C, Gu CD, Wang J, Yang XN, Mao WM, Wang Q, Qiao GB, Cheng Y, Xu L, Wang CL, Chen MW, Kang X, Yan W, ... ... Wu YL, et al. Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 -Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900075. PMID 31194613 DOI: 10.1200/JCO.19.00075 |
0.395 |
|
| 2019 |
Li Y, Wu YL. The second wave of checkpoint inhibitors with chemotherapy for advanced non-small-cell lung cancer. The Lancet. Oncology. 20: 889-891. PMID 31122902 DOI: 10.1016/S1470-2045(19)30148-2 |
0.321 |
|
| 2019 |
Park K, Bennouna J, Boyer M, Hida T, Hirsh V, Kato T, Lu S, Mok T, Nakagawa K, O'Byrne K, Paz-Ares L, Schuler M, Sibilot DM, Tan EH, Tanaka H, ... Wu YL, et al. Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 132: 126-131. PMID 31097085 DOI: 10.1016/J.Lungcan.2019.04.014 |
0.374 |
|
| 2019 |
Zhang YC, Chen ZH, Zhang XC, Xu CR, Yan HH, Xie Z, Chuai SK, Ye JY, Han-Zhang H, Zhang Z, Bai XY, Su J, Gan B, Yang JJ, Li WF, ... ... Wu YL, et al. Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial. Ebiomedicine. PMID 31027916 DOI: 10.1016/j.ebiom.2019.04.030 |
0.355 |
|
| 2019 |
Yin K, Li YS, Zheng MM, Jiang BY, Li WF, Yang JJ, Tu HY, Zhou Q, Zhong WZ, Yang XN, Chen HJ, Yan HH, Li LL, Wu YL, Zhang XC. A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases. Lung Cancer (Amsterdam, Netherlands). 131: 134-138. PMID 31027690 DOI: 10.1016/j.lungcan.2019.03.015 |
0.342 |
|
| 2019 |
Zhang C, Leighl NB, Wu YL, Zhong WZ. Emerging therapies for non-small cell lung cancer. Journal of Hematology & Oncology. 12: 45. PMID 31023335 DOI: 10.1186/s13045-019-0731-8 |
0.331 |
|
| 2019 |
Zhang XC, Wang J, Shao GG, Wang Q, Qu X, Wang B, Moy C, Fan Y, Albertyn Z, Huang X, Zhang J, Qiu Y, Platero S, Lorenzi MV, Zudaire E, ... ... Wu YL, et al. Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients. Nature Communications. 10: 1772. PMID 30992440 DOI: 10.1038/s41467-019-09762-1 |
0.326 |
|
| 2019 |
Song Y, Wu YL, Cao LJ, Chen JH, Ma ZY, Cui JW, Wang J, Liu HB, Ding JY, Hu M. Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy: A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE, CTONG1304). American Journal of Clinical Oncology. PMID 30950859 DOI: 10.1097/COC.0000000000000538 |
0.343 |
|
| 2019 |
Wu YL, Zhou C, Lu S, Qin S, Pan H, Wu G, Cheng Y, Liu X, Han B, Zhu Y, Zhong Z, Huang C, Chen L, Liang H, Li E, et al. Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study. Lung Cancer (Amsterdam, Netherlands). 130: 18-24. PMID 30885342 DOI: 10.1016/j.lungcan.2019.01.016 |
0.409 |
|
| 2019 |
Xia J, Zhong WZ, Wu YL. The superstars of precision medicine-EGFR inhibitors in adjuvant treatment of lung cancer. Journal of Thoracic Disease. 11: E11-E13. PMID 30863616 DOI: 10.21037/jtd.2018.12.72 |
0.355 |
|
| 2019 |
Zheng MM, Li YS, Jiang BY, Tu HY, Tang WF, Yang JJ, Zhang XC, Ye JY, Yan HH, Su J, Zhou Q, Zhong WZ, Yang XN, Guo WB, Chuai S, ... ... Wu YL, et al. Brief Report: Clinical Utility of Cerebrospinal Fluid Cell Free-DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 30659989 DOI: 10.1016/j.jtho.2019.01.007 |
0.339 |
|
| 2019 |
Wu YL, Lu S, Cheng Y, Zhou C, Wang J, Mok T, Zhang L, Tu HY, Wu L, Feng J, Zhang Y, Luft AV, Zhou J, Ma Z, Lu Y, et al. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced Non-Small Cell Lung Cancer: CheckMate 078 Randomized Phase III Clinical Trial. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 30659987 DOI: 10.1016/J.Jtho.2019.01.006 |
0.357 |
|
| 2019 |
Cheng J, Yang J, Wu Y. MET second-site mutations in EGFR-mutant, MET-amplified non-small cell lung cancer after resistance to combinatorial targeted therapy. Journal of Clinical Oncology. 37: e20730-e20730. DOI: 10.1200/JCO.2019.37.15_SUPPL.E20730 |
0.334 |
|
| 2019 |
Cheng J, Yang J, Wu Y. Impact of next-generation sequencing on clinical outcomes in advanced EGFR-mutant lung cancer patients after resistance to osimertinib. Journal of Clinical Oncology. 37: e20726-e20726. DOI: 10.1200/JCO.2019.37.15_SUPPL.E20726 |
0.318 |
|
| 2019 |
Li X, Yang J, Wu Y. Association of allele frequency of EGFR mutation with efficacy of EGFR TKIs in advanced non-small cell lung cancer. Journal of Clinical Oncology. 37: e20678-e20678. DOI: 10.1200/JCO.2019.37.15_SUPPL.E20678 |
0.36 |
|
| 2019 |
Lu C, Cheng J, Kang J, Yao Y, Li X, Zhang X, Zhou Q, Tu H, Wu Y, Yang J. Clinical outcomes of NSCLC patients with acquired RET rearrangement after resistance to osimertinib. Journal of Clinical Oncology. 37: e20626-e20626. DOI: 10.1200/JCO.2019.37.15_SUPPL.E20626 |
0.319 |
|
| 2019 |
Kang J, Li X, Cheng J, Chen H, Zhang X, Tu H, Zhou Q, Wu Y, Yang J. The continued osimertinib plus chemotherapy overcoming resistance after histologic transformation in EGFR-mutant lung adenocarcinoma treated with osimertinib. Journal of Clinical Oncology. 37: e20615-e20615. DOI: 10.1200/JCO.2019.37.15_SUPPL.E20615 |
0.339 |
|
| 2019 |
Zhou Q, Wu L, Feng L, An T, Cheng Y, Zhou J, Li J, Feng JF, Zhang L, Han B, Xu W, Zhu L, Xu L, Xu X, Luo FR, ... Wu Y, et al. Safety and efficacy of abivertinib (AC0010), a third-generation EGFR tyrosine kinase inhibitor, in Chinese patients with EGFR-T790M positive non-small cell lung cancer (NCSLC). Journal of Clinical Oncology. 37: 9091-9091. DOI: 10.1200/JCO.2019.37.15_SUPPL.9091 |
0.324 |
|
| 2019 |
Tan D, Geater S, Yu C, Tsai C, Hsia T, Zhou J, Chen J, Lin M, Yu P, He J, Li W, Lu Y, Sriuranpong V, Yang C, Sen P, ... ... Wu Y, et al. First-line ceritinib versus chemotherapy in patients (pts) with advanced ALK rearranged (ALK+) non-small cell lung cancer (NSCLC): ASCEND-4 Asian subgroup analysis Annals of Oncology. 30: v599-v600. DOI: 10.1093/annonc/mdz259.016 |
0.375 |
|
| 2019 |
Zhang Y, Zhou Q, Chen Z, Zhang M, Yang J, Tu H, Zhang X, Xu C, Yan H, Peng X, Bai X, Chuai S, Ye J, Wu Y. The spatiotemporal evolution of EGFR C797S mutation in EGFR-mutant non-small cell lung cancer: opportunities for third-generation EGFR inhibitors re-challenge Science Bulletin. 64: 499-503. DOI: 10.1016/J.SCIB.2019.03.031 |
0.349 |
|
| 2018 |
Wu YL, Xu CR, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Märten A, Fan J, Peil B, Zhou C. Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring mutations: subgroup analysis of the LUX-Lung 6 trial. Oncotargets and Therapy. 11: 8575-8587. PMID 30584317 DOI: 10.2147/OTT.S160358 |
0.413 |
|
| 2018 |
John T, Akamatsu H, Delmonte A, Su WC, Lee JS, Chang GC, Huang X, Jenkins S, Wu YL. EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 126: 133-138. PMID 30527177 DOI: 10.1016/j.lungcan.2018.10.027 |
0.396 |
|
| 2018 |
Wu YL, Lee V, Liam CK, Lu S, Park K, Srimuninnimit V, Wang J, Zhou C, Appius A, Button P, Hooper G, Palma JF, Schulze K, Scudder S, Shames DS, et al. Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies. Lung Cancer (Amsterdam, Netherlands). 126: 1-8. PMID 30527172 DOI: 10.1016/J.Lungcan.2018.10.004 |
0.315 |
|
| 2018 |
Xu ST, Xi JJ, Zhong WZ, Mao WM, Wu L, Shen Y, Liu YY, Chen C, Cheng Y, Xu L, Wang J, Fei K, Li XF, Li J, Huang C, ... ... Wu YL, et al. The unique spatial-temporal treatment failure patterns of adjuvant gefitinib therapy: A post-hoc analysis of the ADJUVANT trial (CTONG 1104). Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 30521970 DOI: 10.1016/j.jtho.2018.11.020 |
0.309 |
|
| 2018 |
Chen RL, Zhao J, Zhang XC, Lou NN, Chen HJ, Yang X, Su J, Xie Z, Zhou Q, Tu HY, Zhong WZ, Yan HH, Guo WB, Wu YL, Yang JJ. Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression. Bmc Cancer. 18: 1171. PMID 30477470 DOI: 10.1186/s12885-018-5078-y |
0.339 |
|
| 2018 |
Zhang C, Li SL, Nie Q, Dong S, Shao Y, Yang XN, Wu YL, Yang Y, Zhong WZ. Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small-Cell Lung Cancer with ALK-rearrangement: A Brief Report. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 30408570 DOI: 10.1016/j.jtho.2018.10.161 |
0.317 |
|
| 2018 |
Yin ZJ, Tu HY, Fu M, Zhong WZ, An SJ, Yan HH, Chen HJ, Lin HR, Wu YL. Impact of menopausal status and HER-2/neu protein on efficacy of EGFR-TKI in mutant patients with non-small cell lung cancer. Journal of Cancer. 9: 2987-2993. PMID 30210620 DOI: 10.7150/jca.25679 |
0.338 |
|
| 2018 |
Wu YL, Zhang L, Kim DW, Liu X, Lee DH, Yang JC, Ahn MJ, Vansteenkiste JF, Su WC, Felip E, Chia V, Glaser S, Pultar P, Zhao S, Peng B, et al. Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Endothelial Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2018777326. PMID 30156984 DOI: 10.1200/JCO.2018.77.7326 |
0.32 |
|
| 2018 |
Song Y, Zhou Q, Zhang X, Chen GY, Zhong DS, Yu Z, Yu P, Zhang YP, Chen JH, Hu Y, Feng GS, Song X, Shi Q, Yang LL, Yao LD, ... ... Wu YL, et al. Factors associated with gene aberration test status and treatment decision in patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer: A multicenter survey in China (CTONG 1506). Lung Cancer (Amsterdam, Netherlands). 123: 7-13. PMID 30089597 DOI: 10.1016/j.lungcan.2018.06.008 |
0.345 |
|
| 2018 |
Su S, Dong ZY, Xie Z, Yan LX, Li YF, Su J, Liu SY, Yin K, Chen RL, Huang SM, Chen ZH, Yang JJ, Tu HY, Zhou Q, Zhong WZ, ... ... Wu YL, et al. Strong PD-L1 expression predicts poor response and de novo resistance to EGFR TKIs among non-small cell lung cancer patients with EGFR mutation. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 30056164 DOI: 10.1016/j.jtho.2018.07.016 |
0.349 |
|
| 2018 |
Wu YL, Wang CL, Liao ML, Guan ZZ, Gao CY, Lu S, Zhao MF, Wang J, Liu XQ, Yang JJ, Liang J, Mao WM, Han BH, Zhang XC, Song Y, et al. A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. Translational Lung Cancer Research. 7: 428-436. PMID 30050780 DOI: 10.21037/tlcr.2018.04.15 |
0.323 |
|
| 2018 |
Wang Z, Cheng Y, An T, Gao H, Wang K, Zhou Q, Hu Y, Song Y, Ding C, Peng F, Liang L, Hu Y, Huang C, Zhou C, Shi Y, ... ... Wu YL, et al. Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial. The Lancet. Respiratory Medicine. PMID 30017884 DOI: 10.1016/S2213-2600(18)30264-9 |
0.308 |
|
| 2018 |
Kang J, Chen HJ, Zhang XC, Su J, Zhou Q, Tu HY, Wang Z, Wang BC, Zhong WZ, Yang XN, Chen ZH, Ding Y, Wu X, Wang M, Fu JG, ... ... Wu YL, et al. Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer. Thoracic Cancer. PMID 29978950 DOI: 10.1111/1759-7714.12791 |
0.369 |
|
| 2018 |
Wu YL, Lu S, Lu Y, Zhou J, Shi YK, Sriuranpong V, Ho JCM, Ong CK, Tsai CM, Chung CH, Wilner KD, Tang Y, Masters ET, Selaru P, Mok TS. Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 29966800 DOI: 10.1016/J.Jtho.2018.06.012 |
0.37 |
|
| 2018 |
Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Lee M, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, ... Wu YL, et al. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2018787994. PMID 29864379 DOI: 10.1200/Jco.2018.78.7994 |
0.36 |
|
| 2018 |
Zhang Q, Zhang XC, Yang JJ, Yang ZF, Bai Y, Su J, Wang Z, Zhang Z, Shao Y, Zhou Q, Kang J, Ke EE, Zhang YC, Dong ZY, Chen ZH, ... ... Wu YL, et al. EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Osimertinib. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 29857056 DOI: 10.1016/j.jtho.2018.05.024 |
0.304 |
|
| 2018 |
Wu YL, Herbst RS, Mann H, Rukazenkov Y, Marotti M, Tsuboi M. ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection. Clinical Lung Cancer. PMID 29789220 DOI: 10.1016/j.cllc.2018.04.004 |
0.331 |
|
| 2018 |
Wu YL, Sequist LV, Tan EH, Geater SL, Orlov S, Zhang L, Lee KH, Tsai CM, Kato T, Barrios CH, Schuler M, Hirsh V, Yamamoto N, O'Byrne K, Boyer M, et al. Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials. Clinical Lung Cancer. PMID 29653820 DOI: 10.1016/J.Cllc.2018.03.009 |
0.383 |
|
| 2018 |
Wu YL, Yang JC, Kim DW, Lu S, Zhou J, Seto T, Yang JJ, Yamamoto N, Ahn MJ, Takahashi T, Yamanaka T, Kemner A, Roychowdhury D, Paolini J, Usari T, et al. Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017755587. PMID 29596029 DOI: 10.1200/JCO.2017.75.5587 |
0.337 |
|
| 2018 |
Wu YL, Zhong WZ. Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer - Authors' reply. The Lancet. Oncology. 19: e127. PMID 29508752 DOI: 10.1016/S1470-2045(18)30133-5 |
0.353 |
|
| 2018 |
Horn L, Wu Y, Reck M, Wakelee HA, Liang C, Tan F, Harrow K, Oertel V, Dukart G, Mok T. eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps9115 |
0.322 |
|
| 2018 |
Chen R, Tu H, Chen H, Zhou Q, Wu Y, Yan H, Zhang X, Zhang Z, Ye J, Zhong W, Wu J, Yang J. Development of genetic profiles-based nomograms for predicting survival among EGFR-mutant lung cancer. Journal of Clinical Oncology. 36: e21219-e21219. DOI: 10.1200/jco.2018.36.15_suppl.e21219 |
0.316 |
|
| 2018 |
Kang J, Zhang X, Chen H, Zhou Q, Tu H, Li W, Wu Y, Yang J. Uncommon ALK fusion partners in advanced ALK-positive non-small-cell lung cancer. Journal of Clinical Oncology. 36: 8561-8561. DOI: 10.1200/JCO.2018.36.15_SUPPL.8561 |
0.348 |
|
| 2018 |
Yang X, Zhong W, Ben X, Qiao G, Wang Q, Wang C, Luo H, Wang Z, Yan H, Liu S, Wu Y. Final overall survival for CSLC 0501: Phase 3 study of adjuvant versus neoadjuvant chemotherapy with docetaxel combined carboplatin for resectable stageⅠB-ⅢA non-small cell lung cancer. Journal of Clinical Oncology. 36: 8508-8508. DOI: 10.1200/jco.2018.36.15_suppl.8508 |
0.326 |
|
| 2018 |
Wu Y, Lu S, Cheng Y, Zhou C, Wang J, Mok T, Zhang L, Tu H, Wu L, Feng J, Zhang Y, Luft AV, Zhou J, Ma Z, Lu Y, et al. Abstract CT114: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer (NSCLC): results of the phase 3 CheckMate 078 study Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Ct114 |
0.345 |
|
| 2017 |
Goto K, CHYang J, Kim DW, Lu S, Zhou J, Seto T, Yang JJ, Paolini J, Roychowdhury D, Wu YL. Phase II study of Crizotinib in East Asian patients (pts) with ROS1+ advanced non-small cell lung cancer (NSCLC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 28: ix91. PMID 32120732 DOI: 10.1093/annonc/mdx697.074 |
0.351 |
|
| 2017 |
Su J, Zhong W, Zhang X, Huang Y, Yan H, Yang J, Dong Z, Xie Z, Zhou Q, Huang X, Lu D, Yan W, Wu YL. Molecular characteristics and clinical outcomes of EGFR exon 19 indel subtypes to EGFR TKIs in NSCLC patients. Oncotarget. 8: 111246-111257. PMID 29340050 DOI: 10.18632/oncotarget.22768 |
0.344 |
|
| 2017 |
Wu YL, Hirsh V, Sequist LV, Hu CP, Feng J, Lu S, Huang Y, Schuler M, Mok T, Yamamoto N, O'Byrne K, Geater SL, Zhou C, Massey D, Märten A, et al. Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6). The Patient. PMID 29178024 DOI: 10.1007/S40271-017-0287-Z |
0.372 |
|
| 2017 |
Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, Liu YY, Chen C, Cheng Y, Xu L, Wang J, Fei K, Li XF, Li J, Huang C, ... ... Wu YL, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. The Lancet. Oncology. PMID 29174310 DOI: 10.1016/S1470-2045(17)30729-5 |
0.331 |
|
| 2017 |
Tu HY, Ke EE, Yang JJ, Sun YL, Yan HH, Zheng MY, Bai XY, Wang Z, Su J, Chen ZH, Zhang XC, Dong ZY, Wu SP, Jiang BY, Chen HJ, ... ... Wu YL, et al. A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 114: 96-102. PMID 29173773 DOI: 10.1016/j.lungcan.2017.11.005 |
0.375 |
|
| 2017 |
Wu YL, Soo RA, Locatelli G, Stammberger U, Scagliotti G, Park K. Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer? Cancer Treatment Reviews. 61: 70-81. PMID 29121501 DOI: 10.1016/j.ctrv.2017.10.003 |
0.311 |
|
| 2017 |
Zhong WZ, Zhou Q, Wu YL. The resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer. Oncotarget. 8: 71358-71370. PMID 29050366 DOI: 10.18632/oncotarget.20311 |
0.322 |
|
| 2017 |
Mok TSK, Kim SW, Wu YL, Nakagawa K, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Shi X, Rukazenkov Y, Haddad V, Thress KS, et al. Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017739250. PMID 28968167 DOI: 10.1200/JCO.2017.73.9250 |
0.348 |
|
| 2017 |
Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. The Lancet. Oncology. PMID 28958502 DOI: 10.1016/S1470-2045(17)30608-3 |
0.38 |
|
| 2017 |
Yang JJ, Zhou C, Huang Y, Feng J, Lu S, Song Y, Huang C, Wu G, Zhang L, Cheng Y, Hu C, Chen G, Zhang L, Liu X, Yan HH, ... ... Wu YL, et al. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial. The Lancet. Respiratory Medicine. PMID 28734822 DOI: 10.1016/S2213-2600(17)30262-X |
0.313 |
|
| 2017 |
Huang SM, Yang JJ, Chen HJ, Wu SP, Bai XY, Zhou Q, Tu HY, Wu YL. Epidermal growth factor receptor is associated with the onset of skeletal related events in non-small cell lung cancer. Oncotarget. PMID 28706141 DOI: 10.18632/oncotarget.18759 |
0.352 |
|
| 2017 |
Nishio M, Kim DW, Wu YL, Nakagawa K, Solomon BJ, Shaw AT, Hashigaki S, Ohki E, Usari T, Paolini J, Polli A, Wilner KD, Mok T. Crizotinib Versus Chemotherapy in Asian Patients with Advanced ALK-positive Non-small Cell Lung Cancer. Cancer Research and Treatment : Official Journal of Korean Cancer Association. PMID 28701030 DOI: 10.4143/Crt.2017.280 |
0.382 |
|
| 2017 |
Zhou Q, Song Y, Zhang X, Chen GY, Zhong DS, Yu Z, Yu P, Zhang YP, Chen JH, Hu Y, Feng GS, Song X, Shi Q, Yang LL, Zhang PH, ... Wu YL, et al. A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506). Bmc Cancer. 17: 462. PMID 28673332 DOI: 10.1186/s12885-017-3451-x |
0.34 |
|
| 2017 |
Liang Z, Cheng Y, Chen Y, Hu Y, Liu WP, Lu Y, Wang J, Wang Y, Wu G, Ying JM, Zhang HL, Zhang XC, Wu YL. EGFR T790M ctDNA testing platforms and their role as companion diagnostics: correlation with clinical outcomes to EGFR-TKIs. Cancer Letters. PMID 28642172 DOI: 10.1016/J.Canlet.2017.06.008 |
0.303 |
|
| 2017 |
Tian HX, Zhang XC, Wang Z, Yang JJ, Guo WB, Chen ZH, Wu YL. Establishment of a Novel Method for Screening Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance Mutations in Lung Cancer. Chinese Medical Journal. 130: 1446-1453. PMID 28584208 DOI: 10.4103/0366-6999.207478 |
0.319 |
|
| 2017 |
Soo RA, Stone EC, Cummings KM, Jett JR, Field JK, Groen HJ, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, ... ... Wu YL, et al. Scientific Advances in Thoracic Oncology 2016. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 28579481 DOI: 10.1016/J.Jtho.2017.05.019 |
0.319 |
|
| 2017 |
Ke EE, Zhou Q, Zhang QY, Su J, Chen ZH, Zhang XC, Xu CR, Yang JJ, Tu HY, Yan HH, Zhang YC, Niu FY, Wu YL. A higher proportion of the EGFR T790M mutation may contribute to the better survival of patients with exon 19 deletions compared with those with L858R. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 28576746 DOI: 10.1016/j.jtho.2017.05.018 |
0.335 |
|
| 2017 |
Li AN, Yang J, Zhang XC, Zhang Z, Su J, Gou LY, Bai Y, Zhou Q, Yang Z, Han-Zhang H, Zhong W, Chuai S, Zhang Q, Xie Z, Gao HF, ... ... Wu YL, et al. Acquired MET Y1248H and D1246N mutations mediate resistance to MET inhibitors in non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28396313 DOI: 10.1158/1078-0432.CCR-16-3273 |
0.326 |
|
| 2017 |
Lee CK, Davies L, Wu YL, Mitsudomi T, Inoue A, Rosell R, Zhou C, Nakagawa K, Thongprasert S, Fukuoka M, Lord S, Marschner I, Tu YK, Gralla RJ, Gebski V, et al. Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. Journal of the National Cancer Institute. 109. PMID 28376144 DOI: 10.1093/Jnci/Djw279 |
0.388 |
|
| 2017 |
Wu YL, Saijo N, Thongprasert S, Yang JC, Han B, Margono B, Chewaskulyong B, Sunpaweravong P, Ohe Y, Ichinose Y, Yang JJ, Mok TS, Young H, Haddad V, Rukazenkov Y, et al. Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. Lung Cancer (Amsterdam, Netherlands). 104: 119-125. PMID 28212993 DOI: 10.1016/j.lungcan.2016.11.022 |
0.366 |
|
| 2017 |
Dong ZY, Zhai HR, Hou QY, Su J, Liu SY, Yan HH, Li YS, Chen ZY, Zhong WZ, Wu YL. Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non-Small Cell Lung Cancer. The Oncologist. 22: 61-69. PMID 28126915 DOI: 10.1634/theoncologist.2016-0150 |
0.386 |
|
| 2017 |
Soria JC, Tan DS, Chiari R, Wu YL, Paz-Ares L, Wolf J, Geater SL, Orlov S, Cortinovis D, Yu CJ, Hochmair M, Cortot AB, Tsai CM, Moro-Sibilot D, Campelo RG, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet (London, England). PMID 28126333 DOI: 10.1016/S0140-6736(17)30123-X |
0.385 |
|
| 2017 |
Dong S, Zhao N, Deng W, Sun HW, Niu FY, Yang JJ, Zhong WZ, Li F, Yan HH, Xu CR, Zhang QY, Yang XN, Liao RQ, Nie Q, Wu YL. Supraclavicular lymph node incisional biopsies have no influence on the prognosis of advanced non-small cell lung cancer patients: a retrospective study. World Journal of Surgical Oncology. 15: 12. PMID 28069039 DOI: 10.1186/s12957-016-1064-5 |
0.313 |
|
| 2017 |
Wu YL, Sequist LV, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Schuler M, Mok T, Yamamoto N, O'Byrne K, Hirsh V, Gibson N, Massey D, et al. EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. British Journal of Cancer. 116: 175-185. PMID 28006816 DOI: 10.1038/Bjc.2016.420 |
0.345 |
|
| 2017 |
Xu CR, Zhong WZ, Zhou Q, Zhang XC, Yang JJ, Wu YL. Heterogeneity of the resistance to gefitinib treatment in a non-small cell lung cancer patient with active epidermal growth factor receptor mutation. Thoracic Cancer. 8: 51-53. PMID 27801981 DOI: 10.1111/1759-7714.12382 |
0.374 |
|
| 2017 |
Mok T, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Rosell R, Jaime JC, Migliorino MR, Pluzanski A, Linke RG, Sbar E, Wang T, Wu Y. Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial. Journal of Clinical Oncology. 35: 0. DOI: 10.1200/Jco.2017.35.18_Suppl.Lba9007 |
0.338 |
|
| 2017 |
Liang Z, Cheng Y, Chen Y, Liu W, Lu Y, Wang J, Wu G, Ying J, Zhang X, Wu Y. Detect T790M in cell free tumor DNA of Chinese advanced non-small cell lung cancer adenocarcinoma patients by different platforms and evaluate clinical outcomes of T790M positive patients with osimertinib monotherapy. Journal of Clinical Oncology. 35: TPS9104-TPS9104. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps9104 |
0.343 |
|
| 2017 |
Li W, Kang J, Zhang X, Jian S, Chen H, Wang Z, Wang B, Zhou Q, Tu H, Wu Y, Yang J. Coexistence of MET exon 14 mutations with EGFR mutations in non-small cell lung cancer. Journal of Clinical Oncology. 35: e20636-e20636. DOI: 10.1200/JCO.2017.35.15_SUPPL.E20636 |
0.305 |
|
| 2017 |
Song Y, Wu Y, Cao L, Chen J, Ma Z, Cui J, Ye X, Ding J. Gefitinib as third-line re-challenge treatment in advanced NSCLC patients with EGFR activating mutation who benefited from first-line gefitinib treatment followed by second-line chemotherapy. Journal of Clinical Oncology. 35: 9035-9035. DOI: 10.1200/JCO.2017.35.15_suppl.9035 |
0.31 |
|
| 2017 |
Tu H, Ke E, Sun Y, Zheng M, Yang J, Wang Z, Wu S, Su J, Zhang X, Bai X, Yang X, Zhong W, Yan H, Zhou Q, Wu Y. The predictive value of uncommon EGFR mutation in patients with non-small-cell lung cancer. Journal of Clinical Oncology. 35: 9028-9028. DOI: 10.1200/JCO.2017.35.15_SUPPL.9028 |
0.355 |
|
| 2017 |
Wu Y, Zhong W, Wang Q, Xu S, Mao W, Wu L, Shen Y, Liu Y, Chen C, Cheng Y, Xu L, Wang J, Fei K, Li X, Li J, et al. Gefitinib (G) versus vinorelbine+cisplatin (VP) as adjuvant treatment in stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC) with EGFR-activating mutation (ADJUVANT): A randomized, Phase III trial (CTONG 1104). Journal of Clinical Oncology. 35: 8500-8500. DOI: 10.1200/JCO.2017.35.15_suppl.8500 |
0.313 |
|
| 2017 |
Kang J, Zhang X, Su J, Xie Z, Li W, Wu Y, Yang J. Co-amplification of MET and PIK3CA in NSCLC and data on a PDX mouse model. Journal of Clinical Oncology. 35: 11591-11591. DOI: 10.1200/jco.2017.35.15_suppl.11591 |
0.308 |
|
| 2017 |
Lu S, Zhang L, Cheng Y, Wang J, Wang C, Wang M, Li X, Wu Q, Wu Y. P1.04-010 CheckMate 870: An Open-label Safety Study of Nivolumab in Previously Treated Patients With Non-Small Cell Lung Cancer in Asia Journal of Thoracic Oncology. 12: S1976. DOI: 10.1016/j.jtho.2017.09.869 |
0.34 |
|
| 2017 |
Wu C, Huang T, Wu C, Wan Y, Liu Y, Hsieh M, Wu Y, Fu J. P3.13-001 Clinical Significance of Chest Tomography Characteristics in Non-Small Cell Lung Cancer Patients Who Received Anatomic Resection Journal of Thoracic Oncology. 12: S2315-S2316. DOI: 10.1016/j.jtho.2017.09.1735 |
0.335 |
|
| 2017 |
Wu YL, Zhou Q, Liu X, Zhang L, Zhou J, Wu L, An T, Cheng Y, Zheng X, Hu B, Jiang J, Fang X, Xu W, Xu X. MA16.06 Phase I/II Study of AC0010, Mutant-Selective EGFR Inhibitor, in Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR T790M Mutation Journal of Thoracic Oncology. 12: S437-S438. DOI: 10.1016/J.JTHO.2016.11.510 |
0.37 |
|
| 2017 |
Han J, Zhang Q, Wang B, Zhou Q, Yan L, Zhang Z, Chen H, Su J, Xie Z, Niu F, Wu YL, Chuai S, Yang J, Dong Z. JCES01.24 Molecular Mechanism of Transformation from Adenocarcinoma to Small-Cell Lung Cancer after EGFR-TKI Journal of Thoracic Oncology. 12: S240-S241. DOI: 10.1016/J.JTHO.2016.11.224 |
0.345 |
|
| 2017 |
Han J, Zhang Q, Wang B, Zhou Q, Yan L, Zhang Z, Chen H, Su J, Xie Z, Niu F, Wu YL, Chuai S, Yang J, Dong Z. P3.02b-116 Molecular Mechanism of Transformation from Adenocarcinoma to Small-Cell Lung Cancer after EGFR-TKI Journal of Thoracic Oncology. 12: S1263-S1264. DOI: 10.1016/j.jtho.2016.11.1784 |
0.329 |
|
| 2017 |
Kang J, Chen H, Yang J-, Zhou Q, Tu H, Wang Z, Lin J, Wu YL. P3.02a-020 Clinical Failure to Crizotinib in Patients with Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancers Journal of Thoracic Oncology. 12: S1173-S1174. DOI: 10.1016/J.JTHO.2016.11.1650 |
0.31 |
|
| 2017 |
Zhou J, Lu Y, Chung C, Masters E, Wilner K, Tang Y, Wu YL. P3.02a-014 Patient Reported General Health Status in a Study of Crizotinib Versus Chemotherapy in Patients With Non-Small Cell Lung Cancer (NSCLC) Journal of Thoracic Oncology. 12: S1169. DOI: 10.1016/j.jtho.2016.11.1644 |
0.325 |
|
| 2016 |
Zhang YC, Zhou Q, Wu YL. Emerging challenges of advanced squamous cell lung cancer. Esmo Open. 1: e000129. PMID 28255454 DOI: 10.1136/esmoopen-2016-000129 |
0.34 |
|
| 2016 |
Cicènas S, Geater SL, Petrov P, Hotko Y, Hooper G, Xia F, Mudie N, Wu YL. Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study). Lung Cancer (Amsterdam, Netherlands). 102: 30-37. PMID 27987585 DOI: 10.1016/j.lungcan.2016.10.007 |
0.379 |
|
| 2016 |
Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. The New England Journal of Medicine. PMID 27959700 DOI: 10.1056/Nejmoa1612674 |
0.354 |
|
| 2016 |
Zhang Q, Zhang X, Yan H, Jiang B, Xu C, Yang J, Chen Z, Su J, Wu YL, Zhou Q. Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis. Thoracic Cancer. 7: 648-654. PMID 27755835 DOI: 10.1111/1759-7714.12379 |
0.341 |
|
| 2016 |
Ke EE, Wu YL. EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now? Trends in Pharmacological Sciences. PMID 27717507 DOI: 10.1016/j.tips.2016.09.003 |
0.364 |
|
| 2016 |
Fein L, Wu YL, Sequist LV, Geater SL, Orlov S, Lee KH, Tsai CM, Kato T, Kiura K, Barrios CH, Schuler M, Hirsh V, Yamamoto N, O'Byrne K, Mok T, et al. P1.33: Afatinib Versus Chemotherapy for EGFR Mutation-Positive NSCLC Patients Aged ≥65 Years: Subgroup Analysis of LUX-Lung 3/6: Track: Advanced NSCLC. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: S202-S203. PMID 27676519 DOI: 10.1016/J.Jtho.2016.08.055 |
0.346 |
|
| 2016 |
Zhou Q, Yang JJ, Chen ZH, Zhang XC, Yan HH, Xu CR, Su J, Chen HJ, Tu HY, Zhong WZ, Yang XN, Wu YL. Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial. Journal of Hematology & Oncology. 9: 86. PMID 27619632 DOI: 10.1186/s13045-016-0316-8 |
0.334 |
|
| 2016 |
Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ, Wu YL, Paz-Ares L. Lung cancer: current therapies and new targeted treatments. Lancet (London, England). PMID 27574741 DOI: 10.1016/S0140-6736(16)30958-8 |
0.325 |
|
| 2016 |
Li YS, Jiang BY, Yang JJ, Tu HY, Zhou Q, Guo WB, Yan HH, Wu YL. Leptomeningeal metastases in non-small cell lung cancer patients with EGFR mutations. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 27539328 DOI: 10.1016/j.jtho.2016.06.029 |
0.389 |
|
| 2016 |
Lou NN, Zhang XC, Chen HJ, Zhou Q, Yan LX, Xie Z, Su J, Chen ZH, Tu HY, Yan HH, Wang Z, Xu CR, Jiang BY, Wang BC, Bai XY, ... ... Wu YL, et al. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations. Oncotarget. PMID 27533086 DOI: 10.18632/oncotarget.11218 |
0.342 |
|
| 2016 |
Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W, Pietanza MC, Wu YL, Zielinski C, Thomas M, Felip E, Gold K, Horn L, Aerts J, Nakagawa K, et al. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27458307 DOI: 10.1200/JCO.2016.67.6601 |
0.322 |
|
| 2016 |
Zhang YC, Zhou Q, Wu YL. Efficacy of crizotinib in first-line treatment of adults with ALK-positive advanced NSCLC. Expert Opinion On Pharmacotherapy. PMID 27359268 DOI: 10.1080/14656566.2016.1208171 |
0.351 |
|
| 2016 |
Li Y, Wu YL. Immunotherapy for small-cell lung cancer. The Lancet. Oncology. PMID 27269739 DOI: 10.1016/S1470-2045(16)30159-0 |
0.332 |
|
| 2016 |
Gou LY, Li AN, Yang JJ, Zhang XC, Su J, Yan HH, Xie Z, Lou NN, Liu SY, Dong ZY, Gao HF, Zhou Q, Zhong WZ, Xu CR, Wu YL. The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer. Oncotarget. PMID 27259997 DOI: 10.18632/oncotarget.9697 |
0.344 |
|
| 2016 |
Liu SY, Gou LY, Li AN, Lou NN, Gao HF, Su J, Yang JJ, Zhang XC, Shao Y, Dong ZY, Zhou Q, Zhong WZ, Wu YL. The unique characteristics of MET exon 14 mutation in Chinese non-small cell lung cancer patients. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 27257131 DOI: 10.1016/j.jtho.2016.05.016 |
0.347 |
|
| 2016 |
Lu S, Cheng Y, Zhou CC, Wang J, Yang JC, Zhang PH, Zhang XQ, Wang X, Orlando M, Wu YL. Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. Clinical Lung Cancer. PMID 27236385 DOI: 10.1016/j.cllc.2016.04.003 |
0.36 |
|
| 2016 |
Gao HF, Yang JJ, Chen ZH, Zhang XC, Yan HH, Guo WB, Zhou Q, Gou LY, Dong ZY, Wu YL. Plasma dynamic monitoring of soluble c-Met level for EGFR-TKI treatment in advanced non-small cell lung cancer. Oncotarget. PMID 27213587 DOI: 10.18632/oncotarget.9425 |
0.33 |
|
| 2016 |
Solomon BJ, Cappuzzo F, Felip E, Blackhall FH, Costa DB, Kim DW, Nakagawa K, Wu YL, Mekhail T, Paolini J, Tursi J, Usari T, Wilner KD, Selaru P, Mok TS. Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27022118 DOI: 10.1200/JCO.2015.63.5888 |
0.377 |
|
| 2016 |
Bai XY, Zhang XC, Yang SQ, An SJ, Chen ZH, Su J, Xie Z, Gou LY, Wu YL. Blockade of Hedgehog Signaling Synergistically Increases Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cell Lines. Plos One. 11: e0149370. PMID 26943330 DOI: 10.1371/journal.pone.0149370 |
0.309 |
|
| 2016 |
Ke EE, Wu YL. Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence. Therapeutic Advances in Respiratory Disease. PMID 26929305 DOI: 10.1177/1753465816634545 |
0.399 |
|
| 2016 |
Niu FY, Zhou Q, Yang JJ, Zhong WZ, Chen ZH, Deng W, He YY, Chen HJ, Zeng Z, Ke EE, Zhao N, Zhang N, Sun HW, Zhang QY, Xie Z, ... ... Wu YL, et al. Distribution and prognosis of uncommon metastases from non-small cell lung cancer. Bmc Cancer. 16: 149. PMID 26911831 DOI: 10.1186/s12885-016-2169-5 |
0.301 |
|
| 2016 |
Schuler M, Wu YL, Hirsh V, O'Byrne K, Yamamoto N, Mok T, Popat S, Sequist LV, Massey D, Zazulina V, Yang JC. First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 26823294 DOI: 10.1016/J.Jtho.2015.11.014 |
0.398 |
|
| 2016 |
Pan Y, Brink C, Knap M, Khalil AA, Nyhus CH, McCulloch T, Holm B, Wu YL, Schytte T, Hansen O. Acute esophagitis for patients with local-regional advanced non small cell lung cancer treated with concurrent chemoradiotherapy. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 26803187 DOI: 10.1016/j.radonc.2016.01.007 |
0.336 |
|
| 2016 |
Li AN, Yang J, Zhang X, Wu Y. Impact of different MET alterations on the efficacy of crizotinib in non-small-cell lung cancer. Journal of Clinical Oncology. 34: e20622-e20622. DOI: 10.1200/JCO.2016.34.15_SUPPL.E20622 |
0.347 |
|
| 2016 |
Han J, Zhang Q, Wang B, Zhou Q, Yan L, Chen H, Wang Z, Tu H, Su J, Xie Z, Niu F, Wu Y, Yang J. Molecular mechanism of transformation from adenocarcinoma to small-cell lung cancer after EGFR-TKI. Journal of Clinical Oncology. 34: e20601-e20601. DOI: 10.1200/jco.2016.34.15_suppl.e20601 |
0.345 |
|
| 2016 |
Yang J, Yang L, Farnsworth A, Handzel A, Coleman T, Morgan S, Wu Y. Preliminary results of a phase Ib trial of savolitinib combined with gefitinib in EGFR-mutant lung cancer. Journal of Clinical Oncology. 34: e20559-e20559. DOI: 10.1200/JCO.2016.34.15_SUPPL.E20559 |
0.349 |
|
| 2016 |
Soria J, Ho SN, Varella-Garcia M, Iafrate AJ, Solomon BJ, Shaw AT, Blackhall FH, Mok T, Wu Y, Pestova E, Siebert FW, Wilner KD, Polli A, Paolini J, Lanzalone S, et al. ALK FISH positivity and crizotinib efficacy in patients (pts) with non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 34: 9062-9062. DOI: 10.1200/Jco.2016.34.15_Suppl.9062 |
0.341 |
|
| 2016 |
Lou NN, Wu Y, Yang J, Zhang X, Zhou Q, Su J, Chen H, Wang Z, Bai X, Wang B. Response to tyrosine kinase inhibitors in advanced non-small-cell lung cancer with concomitant c-MET overexpression and EGFR mutation. Journal of Clinical Oncology. 34: 9054-9054. DOI: 10.1200/JCO.2016.34.15_SUPPL.9054 |
0.351 |
|
| 2016 |
Goto K, Yang JC, Kim D, Lu S, Seto T, Yang J, Yamamoto N, Ahn M, Takahashi T, Yamanaka T, Kemner AM, Roychowdhury D, Paolini J, Wilner KD, Wu Y. Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 34: 9022-9022. DOI: 10.1200/JCO.2016.34.15_SUPPL.9022 |
0.352 |
|
| 2016 |
Wu Y, Kim D, Felip E, Zhang L, Liu X, Zhou CC, Lee DH, Han J, Krohn A, Lebouteiller R, Xu C, Squires M, Akimov M, Tan DS. Phase (Ph) II safety and efficacy results of a single-arm ph ib/II study of capmatinib (INC280) + gefitinib in patients (pts) with EGFR-mutated (mut), cMET-positive (cMET+) non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 34: 9020-9020. DOI: 10.1200/JCO.2016.34.15_SUPPL.9020 |
0.315 |
|
| 2016 |
Govindan R, Senan S, Dickgreber NJ, Provencio M, Wu Y, Syrigos KN, Parente B, Chouaki N, Hossain A, San Antonio B, Winfree KB, Vokes EE. Safety and resource use in the PROCLAIM study comparing 2 regimens of concurrent chemoradiation followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 34: 8529-8529. DOI: 10.1200/JCO.2016.34.15_SUPPL.8529 |
0.353 |
|
| 2016 |
Mok T, Ladrera G, Srimuninnimit V, Sriuranpong V, Yu CJ, Thongprasert S, Sandoval-Tan J, Lee JS, Fuerte F, Shames DS, Klughammer B, Truman M, Perez-Moreno P, Wu YL. Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer Lung Cancer. 98: 1-8. DOI: 10.1016/j.lungcan.2016.04.023 |
0.356 |
|
| 2015 |
Asamura H, Chansky K, Crowley J, Goldstraw P, Rusch VW, Vansteenkiste JF, Watanabe H, Wu YL, Zielinski M, Ball D, Rami-Porta R. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 10: 1675-84. PMID 26709477 DOI: 10.1097/JTO.0000000000000678 |
0.316 |
|
| 2015 |
Paz-Ares L, Hirsh V, Zhang L, de Marinis F, Yang JC, Wakelee HA, Seto T, Wu YL, Novello S, Juhász E, Arén O, Sun Y, Schmelter T, Ong TJ, Peña C, et al. MISSION Trial - A phase III, multi-center, placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly non-squamous NSCLC after 2 or 3 previous treatment regimens. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 26551592 DOI: 10.1097/JTO.0000000000000693 |
0.305 |
|
| 2015 |
Li F, Zhong WZ, Niu FY, Zhao N, Yang JJ, Yan HH, Wu YL. Multiple primary malignancies involving lung cancer. Bmc Cancer. 15: 696. PMID 26466785 DOI: 10.1186/s12885-015-1733-8 |
0.331 |
|
| 2015 |
Lei YY, Yang JJ, Zhang XC, Zhong WZ, Zhou Q, Tu HY, Tian HX, Guo WB, Yang LL, Yan HH, Chen HJ, Xie Z, Su J, Han JF, Wu YL. Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC. Clinical Lung Cancer. PMID 26454342 DOI: 10.1016/j.cllc.2015.09.002 |
0.316 |
|
| 2015 |
Zhong WZ, Su J, Xu FP, Zhai HR, Zhang XC, Yang XN, Chen ZY, Chen ZH, Li W, Dong S, Zhou Q, Yang JJ, Liu YH, Wu YL. Rare discrepancies in a driver gene alteration within histologically heterogeneous primary lung cancers. Lung Cancer (Amsterdam, Netherlands). PMID 26391021 DOI: 10.1016/j.lungcan.2015.09.007 |
0.303 |
|
| 2015 |
Lei YY, Yang JJ, Zhong WZ, Chen HJ, Yan HH, Han JF, Yang LL, Wu YL. Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases. Journal of Thoracic Disease. 7: 1181-8. PMID 26380734 DOI: 10.3978/j.issn.2072-1439.2015.06.04 |
0.319 |
|
| 2015 |
Liu SY, Mok T, Wu YL. Novel targeted agents for the treatment of lung cancer in China. Cancer. 121: 3089-96. PMID 26331815 DOI: 10.1002/Cncr.29522 |
0.314 |
|
| 2015 |
Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Lee DH, Liu Y, Yoh K, Zhou JY, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. The Lancet. Oncology. PMID 26159065 DOI: 10.1016/S1470-2045(15)00121-7 |
0.393 |
|
| 2015 |
Ahn JS, Ahn YC, Kim JH, Lee CG, Cho EK, Lee KC, Chen M, Kim DW, Kim HK, Min YJ, Kang JH, Choi JH, Kim SW, Zhu G, Wu YL, et al. Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26150444 DOI: 10.1200/JCO.2014.60.0130 |
0.355 |
|
| 2015 |
Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, et al. Final overall survival results from a randomised, Phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 26141208 DOI: 10.1093/annonc/mdv276 |
0.392 |
|
| 2015 |
Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, Lu S, Cheng Y, Han B, Chen L, Huang C, Qin S, Zhu Y, Pan H, Liang H, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study†. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 26105600 DOI: 10.1093/annonc/mdv270 |
0.389 |
|
| 2015 |
Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, Massey D, Zazulina V, Wu YL. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. The Lancet. Oncology. 16: 830-8. PMID 26051236 DOI: 10.1016/S1470-2045(15)00026-1 |
0.356 |
|
| 2015 |
Niu FY, Wu YL. Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib. Oncotargets and Therapy. 8: 999-1007. PMID 25999733 DOI: 10.2147/OTT.S64664 |
0.383 |
|
| 2015 |
Zhong W, Yang X, Yan H, Zhang X, Su J, Chen Z, Liao R, Nie Q, Dong S, Zhou Q, Yang J, Tu H, Wu YL. Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status. Journal of Hematology & Oncology. 8: 54. PMID 25981169 DOI: 10.1186/s13045-015-0151-3 |
0.354 |
|
| 2015 |
Geater SL, Xu CR, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Palmer M, Shi Y, Lungershausen J, Wu YL. Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non-small-cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 10: 883-9. PMID 25933111 DOI: 10.1097/JTO.0000000000000517 |
0.383 |
|
| 2015 |
Lee CK, Wu YL, Ding PN, Lord SJ, Inoue A, Zhou C, Mitsudomi T, Rosell R, Pavlakis N, Links M, Gebski V, Gralla RJ, Yang JC. Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1958-65. PMID 25897154 DOI: 10.1200/JCO.2014.58.1736 |
0.353 |
|
| 2015 |
Zhai H, Zhong W, Yang X, Wu YL. Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer. Translational Lung Cancer Research. 4: 82-93. PMID 25806348 DOI: 10.3978/j.issn.2218-6751.2014.11.08 |
0.382 |
|
| 2015 |
Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. The Lancet. Oncology. 16: 141-51. PMID 25589191 DOI: 10.1016/S1470-2045(14)71173-8 |
0.343 |
|
| 2015 |
Wang Z, Yan HH, Yang JJ, Wang BC, Chen HJ, Zhou Q, Xu CR, Jiang BY, Wu YL. Venous thromboembolism risk factors in Chinese non-small cell lung cancer patients. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 23: 635-41. PMID 25155313 DOI: 10.1007/s00520-014-2405-y |
0.311 |
|
| 2015 |
Yang J, Lei Y, Zhang X, Zhou Q, Yan Hh, Chen H, Tu H, Wang Z, Xu C, Su J, Huang Y, Wang B, Jiang B, Bai X, Zhong W, ... ... Wu Y, et al. First-line versus second or further-line crizotinib for trial patients with advanced non-small-cell lung cancer harboring ALK rearrangements. Journal of Clinical Oncology. 33: e19139-e19139. DOI: 10.1200/JCO.2015.33.15_SUPPL.E19139 |
0.321 |
|
| 2015 |
Chen R, Yang J, Zhang X, Lou N, Chen H, Zhou Q, Su J, Guo W, Chen J, Tu H, Sun Y, Wu Y. ROS1 rearrangement coexists with EGFR mutation in non-small-cell lung cancer. Journal of Clinical Oncology. 33: e19003-e19003. DOI: 10.1200/JCO.2015.33.15_SUPPL.E19003 |
0.371 |
|
| 2015 |
Li AN, Yang J, Zhang X, Wu Y. Crizotinib in advanced non-small-cell lung cancer with de novo c-Met overexpression. Journal of Clinical Oncology. 33: 8090-8090. DOI: 10.1200/JCO.2015.33.15_SUPPL.8090 |
0.336 |
|
| 2015 |
Lou N, Yang J, Zhang X, Zhou Q, Chen H, Wang Z, Su J, Xie Z, Jiang B, Chen Z, Bai X, Wu Y. Response to tyrosine kinase inhibtors in non-small-cell lung cancer with concomitant c-MET overexpression and driver genes. Journal of Clinical Oncology. 33: 8089-8089. DOI: 10.1200/jco.2015.33.15_suppl.8089 |
0.307 |
|
| 2015 |
Li A, Niu FY, Han JF, Lou NN, Yang JJ, Zhang XC, Zhou Q, Xie Z, Su J, Zhao N, Huang Y, Wu YL. Predictive and prognostic value of de novo MET expression in patients with advanced non-small-cell lung cancer Lung Cancer. 90: 375-380. DOI: 10.1016/j.lungcan.2015.10.021 |
0.333 |
|
| 2014 |
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. The New England Journal of Medicine. 371: 2167-77. PMID 25470694 DOI: 10.1056/Nejmoa1408440 |
0.316 |
|
| 2014 |
Zhou Q, Cheng Y, Yang JJ, Zhao MF, Zhang L, Zhang XC, Chen ZH, Yan HH, Song Y, Chen JH, Feng WN, Xu CR, Wang Z, Chen HJ, Zhong WZ, ... ... Wu YL, et al. Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 25: 2385-91. PMID 25281710 DOI: 10.1093/annonc/mdu463 |
0.379 |
|
| 2014 |
Zeng Z, Yan HH, Zhang XC, Zhong WZ, He YY, Guan JL, Niu FY, Xie Z, Huang YS, Xu CR, Dong S, Wu YL. Reduced chemotherapy sensitivity in EGFR-mutant lung cancer patient with frontline EGFR tyrosine kinase inhibitor. Lung Cancer (Amsterdam, Netherlands). 86: 219-24. PMID 25263853 DOI: 10.1016/j.lungcan.2014.09.008 |
0.364 |
|
| 2014 |
Yang JJ, Huang C, Chen GY, Song Y, Cheng Y, Yan HH, Zhou Q, Wu YL. A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung. Bmc Cancer. 14: 684. PMID 25239521 DOI: 10.1186/1471-2407-14-684 |
0.307 |
|
| 2014 |
Wu YL, Lu S, Cheng Y, Zhou C, Wang M, Qin S, Lu Y, Zhang Y, Zhu Y, Song X, Wang X, Barraclough H, Zhang X, Chi H, Orlando M. Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 85: 401-7. PMID 25082564 DOI: 10.1016/j.lungcan.2014.07.007 |
0.352 |
|
| 2014 |
He YY, Zhang XC, Yang JJ, Niu FY, Zeng Z, Yan HH, Xu CR, Guan JL, Zhong WZ, Yang LL, Guo LH, Wu YL. Prognostic significance of genotype and number of metastatic sites in advanced non-small-cell lung cancer. Clinical Lung Cancer. 15: 441-7. PMID 25044104 DOI: 10.1016/j.cllc.2014.06.006 |
0.305 |
|
| 2014 |
Popat S, Mok T, Yang JCH, Wu YL, Lungershausen J, Stammberger U, Griebsch I, Fonseca T, Paz-Ares L. Afatinib in the treatment of EGFR mutation-positive NSCLC - A network meta-analysis Lung Cancer. 85: 230-238. PMID 24929780 DOI: 10.1016/J.Lungcan.2014.05.007 |
0.333 |
|
| 2014 |
Zhao N, Zhang XC, Yan HH, Yang JJ, Wu YL. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials. Lung Cancer (Amsterdam, Netherlands). 85: 66-73. PMID 24780111 DOI: 10.1016/j.lungcan.2014.03.026 |
0.355 |
|
| 2014 |
Huang L, An SJ, Chen ZH, Su J, Yan HH, Wu YL. MET expression plays differing roles in non-small-cell lung cancer patients with or without EGFR mutation. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 9: 725-8. PMID 24722158 DOI: 10.1097/JTO.0000000000000105 |
0.389 |
|
| 2014 |
Yang JJ, Zhang XC, Su J, Xu CR, Zhou Q, Tian HX, Xie Z, Chen HJ, Huang YS, Jiang BY, Wang Z, Wang BC, Yang XN, Zhong WZ, Nie Q, ... ... Wu YL, et al. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1383-92. PMID 24443522 DOI: 10.1158/1078-0432.Ccr-13-0699 |
0.351 |
|
| 2014 |
Zhou Q, Zhou CC, Chen GY, Cheng Y, Huang C, Zhang L, Xu CR, Li AW, Yan HH, Su J, Zhang XC, Yang JJ, Wu YL. A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805). Lung Cancer (Amsterdam, Netherlands). 83: 369-73. PMID 24440279 DOI: 10.1016/j.lungcan.2013.12.014 |
0.326 |
|
| 2014 |
Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, Shi Y, Geater SL. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. The Lancet. Oncology. 15: 213-22. PMID 24439929 DOI: 10.1016/S1470-2045(13)70604-1 |
0.402 |
|
| 2014 |
Niu FY, Wu YL. Novel agents and strategies for overcoming EGFR TKIs resistance. Experimental Hematology & Oncology. 3: 2. PMID 24410791 DOI: 10.1186/2162-3619-3-2 |
0.343 |
|
| 2014 |
Gou LY, Wu YL. Prevalence of driver mutations in non-small-cell lung cancers in the People's Republic of China Lung Cancer: Targets and Therapy. 5: 1-9. DOI: 10.2147/LCTT.S40817 |
0.336 |
|
| 2014 |
Zhou Q, Zhang X, Peng B, Yu X, Akimov M, Weber BL, Wu Y. A phase II cluster study of single agent AUY922, BYL719, INC280, LDK378, and MEK162 in Chinese patients with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 32: TPS8122-TPS8122. DOI: 10.1200/JCO.2014.32.15_SUPPL.TPS8122 |
0.325 |
|
| 2014 |
Zhang X, Yang J, Chen H, Xie Z, Zhou Q, Su J, Tu H, Wang Z, Xu C, Huang Y, Jiang B, Wang B, Bai X, Wu Y. MET overexpression as a promising therapeutic target in non-small cell lung cancer with acquired resistance to EGFR TKIs. Journal of Clinical Oncology. 32: e19047-e19047. DOI: 10.1200/JCO.2014.32.15_SUPPL.E19047 |
0.355 |
|
| 2014 |
Zhou Q, Yang J, Zhang X, Chen H, Su J, Tu H, Yan H, Wang Z, Xu C, Huang Y, Jiang B, Wang B, Bai X, Wu Y. Overall survival in patients with advanced non-small cell lung cancer harboring concomitant EGFR mutations and ALK rearrangements: A cohort study. Journal of Clinical Oncology. 32: e19010-e19010. DOI: 10.1200/JCO.2014.32.15_SUPPL.E19010 |
0.397 |
|
| 2014 |
Zhong W, Li W, Yang X, Liao R, Nie Q, Dong S, Zhang X, Wu Y. Accidental intrathoracic disseminated pM1a: Distinguished lung cancer with favorable prognosis. Journal of Clinical Oncology. 32: e18522-e18522. DOI: 10.1200/JCO.2014.32.15_SUPPL.E18522 |
0.321 |
|
| 2014 |
Mok T, Kim D, Wu Y, Solomon BJ, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Tursi J, Blackhall FH. First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014) Journal of Clinical Oncology. 32: 8002-8002. DOI: 10.1200/Jco.2014.32.15_Suppl.8002 |
0.366 |
|
| 2014 |
Zhong W, Yang X, Zhang X, Su J, Yan H, Chen Z, Liao R, Nie Q, Dong S, Wu Y. Phase II study of biomarker guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on EGFR-mutation status. Journal of Clinical Oncology. 32: 7572-7572. DOI: 10.1200/JCO.2014.32.15_SUPPL.7572 |
0.356 |
|
| 2014 |
Wu Y, Sequist L, Hu C, Feng J, Lu S, Huang Y, Li W, Hou M, Schuler M, Mok T, Yamamoto N, O'Byrne K, Hirsh V, Gibson N, Massey D, et al. Detection of Epidermal Growth Factor Receptor (EGFR) Mutations in Circulating Cell-Free DNA in Two Phase III Studies (LUX-Lung 3 and LUX-Lung 6) of Afatinib vs Platinum-Based Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer American Journal of Clinical Pathology. 142: A182-A182. DOI: 10.1093/Ajcp/142.Suppl1.182 |
0.384 |
|
| 2014 |
Wu Y, Geater S, Mok T, O'Byrne K, Schuler M, Sequist L, Yang J, Massey D, O’Brien D, Zazulina V. Epidermal Growth Factor Receptor (EGFR)-Mediated Adverse Events (AEs) in Patients (pts) With EGFR-Mutation Positive (EGFR M+) Non-Small Cell Lung Cancer (NSCLC) Treated With Afatinib (A) International Journal of Radiation Oncology*Biology*Physics. 90: S41. DOI: 10.1016/J.IJROBP.2014.08.223 |
0.356 |
|
| 2014 |
Zhou C, Wu Y, Chen G, Liu X, Zhu Y, Lu S, Feng J, He J, Han B, Wang J, Jiang G, Hu C, Zhang H, Cheng G, Song X, et al. Efficacy and Biomarker Data From BEYOND: A Randomized Phase 3 Study of First-Line Chemotherapy ± Bevacizumab in Chinese Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer International Journal of Radiation Oncology*Biology*Physics. 90: S17. DOI: 10.1016/J.IJROBP.2014.08.165 |
0.331 |
|
| 2013 |
Wu YL, Sun Y, Zhou CC, Zhang L, Yu SY, Ma SL, Han LL, Zhang XQ, Orlando M. Survival without common toxicity criteria grade 3/4 toxicity following second-line treatment with pemetrexed for nonsquamous non-small cell lung cancer in Chinese patients. Chinese Medical Journal. 126: 4624-8. PMID 24342300 DOI: 10.3760/cma.j.issn.0366-6999.20130119 |
0.36 |
|
| 2013 |
Zhang XC, Lu S, Zhang L, Wang CL, Cheng Y, Li GD, Mok T, Huang C, Liu XQ, Wang J, Wang MZ, Zhang YP, Zhou JY, Zhou XY, Lin DM, ... ... Wu YL, et al. [Consensus on dignosis for ALK positive non-small cell lung cancer in China, the 2013 version]. Zhonghua Bing Li Xue Za Zhi Chinese Journal of Pathology. 42: 402-6. PMID 24060077 DOI: 10.3760/Cma.J.Issn.0529-5807.2013.06.012 |
0.38 |
|
| 2013 |
Shi Y, Zhang L, Liu X, Zhou C, Zhang L, Zhang S, Wang D, Li Q, Qin S, Hu C, Zhang Y, Chen J, Cheng Y, Feng J, Zhang H, ... ... Wu YL, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. The Lancet. Oncology. 14: 953-61. PMID 23948351 DOI: 10.1016/S1470-2045(13)70355-3 |
0.365 |
|
| 2013 |
Fei SJ, Zhang XC, Dong S, Cheng H, Zhang YF, Huang L, Zhou HY, Xie Z, Chen ZH, Wu YL. Targeting mTOR to overcome epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer cells. Plos One. 8: e69104. PMID 23874880 DOI: 10.1371/journal.pone.0069104 |
0.333 |
|
| 2013 |
Zeng Z, Chen HJ, Yan HH, Yang JJ, Zhang XC, Wu YL. Sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in males, smokers, and non-adenocarcinoma lung cancer in patients with EGFR mutations. The International Journal of Biological Markers. 28: 249-58. PMID 23873621 DOI: 10.5301/JBM.5000039 |
0.353 |
|
| 2013 |
Zhang XC, Zhang J, Li M, Huang XS, Yang XN, Zhong WZ, Xie L, Zhang L, Zhou M, Gavine P, Su X, Zheng L, Zhu G, Zhan P, Ji Q, ... Wu YL, et al. Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies. Journal of Translational Medicine. 11: 168. PMID 23842453 DOI: 10.1186/1479-5876-11-168 |
0.314 |
|
| 2013 |
Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, Srimuninnimit V, Sriuranpong V, Sandoval-Tan J, Zhu Y, Liao M, Zhou C, Pan H, Lee V, Chen YM, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. The Lancet. Oncology. 14: 777-86. PMID 23782814 DOI: 10.1016/S1470-2045(13)70254-7 |
0.363 |
|
| 2013 |
Bai XY, Lin JY, Zhang XC, Xie Z, Yan HH, Chen ZH, Xu CR, An SJ, Sheng GM, Wu YL. High expression of truncated GLI3 is associated with poor overall survival in patients with non-small cell lung cancer. Cancer Biomarkers : Section a of Disease Markers. 13: 37-47. PMID 23736020 DOI: 10.3233/CBM-130312 |
0.347 |
|
| 2013 |
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. The New England Journal of Medicine. 368: 2385-94. PMID 23724913 DOI: 10.1056/Nejmoa1214886 |
0.32 |
|
| 2013 |
Chen HJ, Yan HH, Yang JJ, Chen ZH, Su J, Zhang XC, Wu YL. Disease flare after EGFR tyrosine kinase inhibitor cessation predicts poor survival in patients with non-small cell lung cancer. Pathology Oncology Research : Por. 19: 833-8. PMID 23716023 DOI: 10.1007/s12253-013-9651-z |
0.334 |
|
| 2013 |
Wu YL, Fukuoka M, Mok TS, Saijo N, Thongprasert S, Yang JC, Chu DT, Yang JJ, Rukazenkov Y. Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study. Lung Cancer (Amsterdam, Netherlands). 81: 280-7. PMID 23540718 DOI: 10.1016/j.lungcan.2013.03.004 |
0.306 |
|
| 2013 |
Chen G, Feng J, Zhou C, Wu YL, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu CP, Hu C, Luo Y, et al. Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 1615-22. PMID 23456778 DOI: 10.1093/annonc/mdt012 |
0.364 |
|
| 2013 |
Hirsch FR, Jänne PA, Eberhardt WE, Cappuzzo F, Thatcher N, Pirker R, Choy H, Kim ES, Paz-Ares L, Gandara DR, Wu YL, Ahn MJ, Mitsudomi T, Shepherd FA, Mok TS. Epidermal growth factor receptor inhibition in lung cancer: status 2012. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 8: 373-84. PMID 23370315 DOI: 10.1097/Jto.0B013E31827Ed0Ff |
0.399 |
|
| 2013 |
Guan JL, Zhong WZ, An SJ, Yang JJ, Su J, Chen ZH, Yan HH, Chen ZY, Huang ZM, Zhang XC, Nie Q, Wu YL. KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy. Annals of Surgical Oncology. 20: 1381-8. PMID 23208128 DOI: 10.1245/s10434-012-2754-z |
0.353 |
|
| 2013 |
Yang JJ, Chen HJ, Yan HH, Zhang XC, Zhou Q, Su J, Wang Z, Xu CR, Huang YS, Wang BC, Yang XN, Zhong WZ, Nie Q, Liao RQ, Jiang BY, ... ... Wu YL, et al. Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 79: 33-9. PMID 23079155 DOI: 10.1016/j.lungcan.2012.09.016 |
0.319 |
|
| 2013 |
Mok T, Nakagawa K, Rosell R, Wu YL, Trygstad C, Capizzi RL, Lee MY, Tsuji F, DeBenedetto R, Goldberg Z, Wang T, Liang JQ, Letrent SP, O'Connell JP, Antic V. Phase III randomized, open label study (ARCHER 1050) of first-line dacomitinib (D) versus gefitinib (G) for advanced (adv) non-small cell lung cancer (NSCLC) in patients (pts) with epidermal growth factor receptor (EGFR) activating mutation(s). Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps8123 |
0.3 |
|
| 2013 |
Wu YL, Zhou C, Hu C, Feng JF, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Massey D, Shi Y, Chen J, Zazulina V, Geater SL. LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. Journal of Clinical Oncology. 31: 8016-8016. DOI: 10.1200/jco.2013.31.15_suppl.8016 |
0.337 |
|
| 2013 |
Mok T, Nakagawa K, Rosell R, Wu Y, Trygstad C, Capizzi R, DeBenedetto R, Goldberg Z, Wang T, Antic V. 92P ARCHER 1050: PHASE III RANDOMIZED STUDY OF 1ST-LINE DACOMITINIB (D) VS GEFITINIB (G) FOR ADVANCED (ADV) NON-SMALL CELL LUNG CANCER (NSCLC) IN PATIENTS (PTS) WITH ACTIVATING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION(S) Lung Cancer. 80: S39-S40. DOI: 10.1016/S0169-5002(13)70311-8 |
0.36 |
|
| 2012 |
Mok TS, Zhou Q, Wu YL. Research and standard care: lung cancer in china. American Society of Clinical Oncology Educational Book / Asco. American Society of Clinical Oncology. Meeting. 432-6. PMID 24451776 DOI: 10.14694/EdBook_AM.2012.32.432 |
0.35 |
|
| 2012 |
Yang JJ, Zhou Q, Liao RQ, Huang YS, Xu CR, Wang Z, Wang BC, Chen HJ, Wu YL. Nedaplatin/Gemcitabine Versus Carboplatin/Gemcitabine in Treatment of Advanced Non-small Cell Lung Cancer: A Randomized Clinical Trial. Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu. 24: 97-102. PMID 23359648 DOI: 10.1007/s11670-012-0097-8 |
0.362 |
|
| 2012 |
Xu C, Zhou Q, Wu YL. Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors? - A literature-based meta-analysis. Journal of Hematology & Oncology. 5: 62. PMID 23050865 DOI: 10.1186/1756-8722-5-62 |
0.378 |
|
| 2012 |
Dong S, Zhang XC, Cheng H, Zhu JQ, Chen ZH, Zhang YF, Xie Z, Wu YL. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Chemotherapy and Pharmacology. 70: 707-16. PMID 22941374 DOI: 10.1007/s00280-012-1946-3 |
0.345 |
|
| 2012 |
An SJ, Chen ZH, Su J, Zhang XC, Zhong WZ, Yang JJ, Zhou Q, Yang XN, Huang L, Guan JL, Nie Q, Yan HH, Mok TS, Wu YL. Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. Plos One. 7: e40109. PMID 22768234 DOI: 10.1371/Journal.Pone.0040109 |
0.3 |
|
| 2012 |
Chen ZY, Zhong WZ, Zhang XC, Su J, Yang XN, Chen ZH, Yang JJ, Zhou Q, Yan HH, An SJ, Chen HJ, Jiang BY, Mok TS, Wu YL. EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. The Oncologist. 17: 978-85. PMID 22673630 DOI: 10.1634/Theoncologist.2011-0385 |
0.329 |
|
| 2012 |
Wu YL, Kim JH, Park K, Zaatar A, Klingelschmitt G, Ng C. Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study. Lung Cancer (Amsterdam, Netherlands). 77: 339-45. PMID 22494567 DOI: 10.1016/j.lungcan.2012.03.012 |
0.365 |
|
| 2012 |
Wu YL, Zhou Q. Clinical trials and biomarker research on lung cancer in China. Expert Opinion On Therapeutic Targets. S45-50. PMID 22313283 DOI: 10.1517/14728222.2011.630663 |
0.304 |
|
| 2012 |
Belani CP, Wu YL, Chen YM, Kim JH, Yang SH, Zhang L, Peterson P, Orlando M. Efficacy and safety of pemetrexed maintenance therapy versus best supportive care in patients from East Asia with advanced, nonsquamous non-small cell lung cancer: an exploratory subgroup analysis of a global, randomized, phase 3 clinical trial. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 567-73. PMID 22157370 DOI: 10.1097/JTO.0b013e31823d4f9d |
0.346 |
|
| 2012 |
Yang L, Wu Y. Gene fusions in non-small-cell lung cancer Lung Cancer Management. 1: 283-292. DOI: 10.2217/LMT.12.41 |
0.314 |
|
| 2012 |
Guan J, Zhong W, An S, Su J, Chen Z, Huang Y, Huang Z, Zhang X, Yang J, Wu YL. KRAS mutation in lung cancer patients: A poor prognostic factor but not a predictive factor of EGFR-TKI and chemotherapy? Journal of Clinical Oncology. 30: e18090-e18090. DOI: 10.1200/jco.2012.30.15_suppl.e18090 |
0.367 |
|
| 2012 |
Wang Z, Wang J, Wu YL, Bai H, Zhang X, An T, Zhuo M, Duan J, Yang L, Wu M. EGFR-TKI benefit for NSCLC patients with EML4-ALK rearrangement. Journal of Clinical Oncology. 30: e18035-e18035. DOI: 10.1200/jco.2012.30.15_suppl.e18035 |
0.338 |
|
| 2012 |
Zhou C, Wu YL, Liu X, Wang C, Chen G, Feng JF, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Luo Y, Chen L, et al. Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 30: 7520-7520. DOI: 10.1200/JCO.2012.30.15_SUPPL.7520 |
0.301 |
|
| 2012 |
Mok T, Wu YL, Thongprasert S, Yu C, Zhang L, Ladrera GE, Srimuninnimit V, Sriuranpong V, Sandoval-Tan J, Zhu Y, Liao M, Zhou C, Pan H, Lee V, Chen Y, et al. A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II. Journal of Clinical Oncology. 30: 7519-7519. DOI: 10.1200/Jco.2012.30.15_Suppl.7519 |
0.307 |
|
| 2012 |
Zhong W, Yang X, Liao R, Nie Q, Su J, Chen Z, Zhang X, An S, Zhou Q, Yang J, Wu YL. A prospective phase II study of induction erlotinib therapy in stage IIIA-N2 non-small cell lung cancer. Journal of Clinical Oncology. 30: 7039-7039. DOI: 10.1200/JCO.2012.30.15_SUPPL.7039 |
0.343 |
|
| 2012 |
Chen H, Yang J, Yan H, Zhang X, Wu Z, Wu Y. Clinical Modes of EGFR Tyrosine Kinase Inhibitor Failure and Subsequent Management in Advanced Non-Small Cell Lung Cancer Annals of Oncology. 23: ix437. DOI: 10.1016/s0923-7534(20)33797-2 |
0.317 |
|
| 2012 |
Bai X, Lin J, Zhang X, Xie Z, Yan H, Chen Z, Xu C, An S, Sheng G, Wu Y. High Expression of Truncated GLI3 is Associated with Poor Overall Survival in Patients with Non-Small-Cell Lung Cancer Annals of Oncology. 23: xi48. DOI: 10.1016/s0923-7534(20)32054-8 |
0.337 |
|
| 2011 |
Sun Y, Shi Y, Zhang L, Liu X, Zhou C, Zhang L, Wang D, Li Q, Zhang S, Qin S, Hu C, Zhang Y, Chen J, Song Y, Feng JF, ... ... Wu YL, et al. A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 7522. PMID 28023247 DOI: 10.1200/jco.2011.29.15_suppl.7522 |
0.328 |
|
| 2011 |
Zhang X, Yin L, Yang X, Yang J, Zhou Q, Xu J, Xie Z, An S, Chen S, Wang R, Zhu G, Gu Y, Zhang X, Wu YL. Detection of EGFR mutations with mutation-specific antibodies in primary lesions of non-small cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 7035. PMID 28020059 DOI: 10.1200/Jco.2011.29.15_Suppl.7035 |
0.309 |
|
| 2011 |
Wu YL, Park K, Soo RA, Sun Y, Tyroller K, Wages D, Ely G, Yang JC, Mok T. INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. Bmc Cancer. 11: 430. PMID 21982342 DOI: 10.1186/1471-2407-11-430 |
0.34 |
|
| 2011 |
Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, Xu CR, Yan HH, Chen HJ, Su J, Zhong WZ, Yang XN, An SJ, Wang BC, Huang YS, Wang Z, ... Wu YL, et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3316-21. PMID 21788562 DOI: 10.1200/JCO.2010.33.3757 |
0.377 |
|
| 2011 |
Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. The Lancet. Oncology. 12: 735-42. PMID 21783417 DOI: 10.1016/S1470-2045(11)70184-X |
0.393 |
|
| 2011 |
Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2866-74. PMID 21670455 DOI: 10.1200/Jco.2010.33.4235 |
0.359 |
|
| 2011 |
Nie Q, Yang XN, An SJ, Zhang XC, Yang JJ, Zhong WZ, Liao RQ, Chen ZH, Su J, Xie Z, Wu YL. CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism. European Journal of Cancer (Oxford, England : 1990). 47: 1962-70. PMID 21616658 DOI: 10.1016/j.ejca.2011.04.018 |
0.311 |
|
| 2011 |
Tsai CM, Au JS, Chang GC, Cheng AC, Zhou C, Wu YL. Safety and efficacy of first-line bevacizumab with chemotherapy in Asian patients with advanced nonsquamous NSCLC: results from the phase IV MO19390 (SAiL) study. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 1092-7. PMID 21512405 DOI: 10.1097/JTO.0b013e318216687d |
0.304 |
|
| 2011 |
Heigener DF, Wu YL, van Zandwijk N, Mali P, Horwood K, Reck M. Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study. Lung Cancer (Amsterdam, Netherlands). 74: 274-9. PMID 21439671 DOI: 10.1016/j.lungcan.2011.02.017 |
0.327 |
|
| 2011 |
Cheng H, An SJ, Dong S, Zhang YF, Zhang XC, Chen ZH, Wu YL. Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib. Journal of Hematology & Oncology. 4: 5. PMID 21255411 DOI: 10.1186/1756-8722-4-5 |
0.368 |
|
| 2011 |
Reck M, Mok TS, Wolf J, Heigener D, Wu YL. Reviewing the safety of erlotinib in non-small cell lung cancer. Expert Opinion On Drug Safety. 10: 147-157. PMID 21138395 DOI: 10.1517/14740338.2011.540799 |
0.351 |
|
| 2010 |
Saijo N, Fukuoka M, Thongprasert S, Ichinose Y, Mitsudomi T, Mok TS, Ohe Y, Park K, Wu YL. Lung cancer working group report. Japanese Journal of Clinical Oncology. 40: i7-12. PMID 20870923 DOI: 10.1093/jjco/hyq121 |
0.35 |
|
| 2010 |
Mok T, Wu YL, Au JS, Zhou C, Zhang L, Perng RP, Park K. Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 5: 1609-15. PMID 20808255 DOI: 10.1097/Jto.0B013E3181E15D55 |
0.377 |
|
| 2010 |
Crinò L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N, Stroiakovski D, Thatcher N, Tsai CM, Wu YL, Zhou C. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. The Lancet. Oncology. 11: 733-40. PMID 20650686 DOI: 10.1016/S1470-2045(10)70151-0 |
0.346 |
|
| 2010 |
Zhang X, Zhang S, Yang X, Yang J, Zhou Q, Yin L, An S, Lin J, Chen S, Xie Z, Zhu M, Zhang X, Wu YL. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Molecular Cancer. 9: 188. PMID 20624322 DOI: 10.1186/1476-4598-9-188 |
0.341 |
|
| 2010 |
Cheng H, An SJ, Zhang XC, Dong S, Zhang YF, Chen ZH, Chen HJ, Guo AL, Lin QX, Wu YL. In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines. Cancer Chemotherapy and Pharmacology. 67: 637-46. PMID 20495920 DOI: 10.1007/s00280-010-1347-4 |
0.381 |
|
| 2010 |
Zhong WZ, Wu YL, Yang XN, Guo AL, Su J, Zhang XC, Luo DL, Wang Z, Chen HJ, Zhou Q, Xu CR, Qiao GB, Liao RQ, Yang JJ, Mok TS. Genetic evolution of epidermal growth factor receptor in adenocarcinoma with a bronchioloalveolar carcinoma component. Clinical Lung Cancer. 11: 160-8. PMID 20439191 DOI: 10.3816/Clc.2010.N.020 |
0.31 |
|
| 2010 |
Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 17: 77-88. PMID 20129249 DOI: 10.1016/J.Ccr.2009.11.022 |
0.356 |
|
| 2010 |
Zhong W, Yang X, Liao R, Nie Q, Zhang X, Su J, Zhou Q, Xu C, Yang J, Wu Y. Induction erlotinib therapy in stage IIIA-N2 non-small cell lung cancer. Journal of Clinical Oncology. 28: TPS284-TPS284. DOI: 10.1200/JCO.2010.28.15_SUPPL.TPS284 |
0.314 |
|
| 2010 |
Tsai C, Zhou C, Jiang G, Guan Z, Zhao WM, Wu Y. Final safety and efficacy data for Asian patients (pts) in the MO19390 (SAiL) trial: First-line bevacizumab (Bv) plus chemotherapy in advanced or recurrent non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 28: e18101-e18101. DOI: 10.1200/jco.2010.28.15_suppl.e18101 |
0.35 |
|
| 2009 |
Park K, Ahn Y, Chen M, Cho E, Kim J, Min Y, Kim H, Zhu G, Heo DS, Wu Y. A multinational phase III randomized trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small cell lung cancer (CCheIN): Interim analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 7538. PMID 27963307 DOI: 10.1200/jco.2009.27.15_suppl.7538 |
0.319 |
|
| 2009 |
Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, Cucevic B, Pereira JR, Yang SH, Madhavan J, Sugarman KP, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet (London, England). 374: 1432-40. PMID 19767093 DOI: 10.1016/S0140-6736(09)61497-5 |
0.337 |
|
| 2009 |
Mok TS, Wu YL, Yu CJ, Zhou C, Chen YM, Zhang L, Ignacio J, Liao M, Srimuninnimit V, Boyer MJ, Chua-Tan M, Sriuranpong V, Sudoyo AW, Jin K, Johnston M, et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5080-7. PMID 19738125 DOI: 10.1200/Jco.2008.21.5541 |
0.379 |
|
| 2009 |
An SJ, Chen ZH, Lin QX, Su J, Chen HJ, Lin JY, Wu YL. The -271 G>A polymorphism of kinase insert domain-containing receptor gene regulates its transcription level in patients with non-small cell lung cancer. Bmc Cancer. 9: 144. PMID 19435508 DOI: 10.1186/1471-2407-9-144 |
0.313 |
|
| 2009 |
Chen HJ, Mok TS, Chen ZH, Guo AL, Zhang XC, Su J, Wu YL. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer. Pathology Oncology Research : Por. 15: 651-8. PMID 19381876 DOI: 10.1007/S12253-009-9167-8 |
0.324 |
|
| 2009 |
Dansin E, Tsai C, Pavlakis N, Laskin J, Griesinger F, Garrido P, Crino L, Wu Y, Jiang G, Thatcher N. 9168 Safety and efficacy of first-line bevacizumab-based therapy in advanced non-small cell lung cancer (NSCLC): results of the SAiL study (MO19390) European Journal of Cancer Supplements. 7: 556. DOI: 10.1016/S1359-6349(09)71881-6 |
0.346 |
|
| 2008 |
Zhu J, Wu Y, Zhong W, Zhang G, Li R, Zhang X, Guo A, Zhang Y, An S, Mok TS. Better survival with epidermal growth factor receptor exon 19 deletion than with exon 21 mutation in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 14501. PMID 27950796 DOI: 10.1200/Jco.2008.26.15_Suppl.14501 |
0.352 |
|
| 2008 |
Lee JS, Ignacio J, Yu C, Zhou C, Wu Y, Chen Y, Zhang L, Jin K, Johnston M, Mok TS. FAST-ACT: A phase II randomized double-blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 8031. PMID 27949057 DOI: 10.1200/Jco.2008.26.15_Suppl.8031 |
0.312 |
|
| 2008 |
Yang J, Wu Y, Yu D, Huang C, Zhou C, Cheng Y, Chen G, Lu S, Han B, Lin Y, Wang J. Multicenter open label study of epoetin beta prevention and treatment for anaemia in non-small cell lung cancer patients treated with chemotherapy prone to induce anaemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 20743. PMID 27948009 DOI: 10.1200/jco.2008.26.15_suppl.20743 |
0.331 |
|
| 2008 |
Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet (London, England). 372: 1809-18. PMID 19027483 DOI: 10.1016/S0140-6736(08)61758-4 |
0.37 |
|
| 2008 |
Zhu JQ, Zhong WZ, Zhang GC, Li R, Zhang XC, Guo AL, Zhang YF, An SJ, Mok TS, Wu YL. Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals. Cancer Letters. 265: 307-17. PMID 18407408 DOI: 10.1016/J.Canlet.2008.02.064 |
0.346 |
|
| 2008 |
Wu Y, Yang J, Huang Y, Zhou Q, Huang Y, Xu C. Docetaxel as salvage chemotherapy in patients with advanced non-small cell lung cancer after failure of cytotoxic agents and gefitinib treatment The Chinese-German Journal of Clinical Oncology. 7: 495-499. DOI: 10.1007/S10330-008-0105-0 |
0.351 |
|
| 2007 |
An SJ, Nie Q, Chen ZH, Lin QX, Wang Z, Xie Z, Chen SL, Huang Y, Zhang AY, Yan JF, Wu HS, Lin JY, Li R, Zhang XC, Guo AL, ... ... Wu YL, et al. KDR expression is associated with the stage and cigarette smoking of the patients with lung cancer. Journal of Cancer Research and Clinical Oncology. 133: 635-42. PMID 17479290 DOI: 10.1007/S00432-007-0214-0 |
0.304 |
|
| 2007 |
Wu YL, Zhong WZ, Li LY, Zhang XT, Zhang L, Zhou CC, Liu W, Jiang B, Mu XL, Lin JY, Zhou Q, Xu CR, Wang Z, Zhang GC, Mok T. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 2: 430-9. PMID 17473659 DOI: 10.1097/01.Jto.0000268677.87496.4C |
0.362 |
|
| 2007 |
Liao R, Wu Y, Yang J, Liu H, Huang Y, Huang Y, Zhou Q, Xu C. P3-110: Tumor histology and N-score predict survival with gefitinib in patients with advanced non-small cell lung cancer Journal of Thoracic Oncology. 2: S726. DOI: 10.1097/01.JTO.0000284086.11418.d3 |
0.33 |
|
| 2007 |
Wu Y, Yang X, Chen G, Gu L, Yang J, Zhong W, Liao R, Zhu Y, Ben X. P2-221: Adjuvant docetaxel plus carboplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer: preliminary results of the Chinese Society of Lung Cancer randomised controlled trial (CSLC201) Journal of Thoracic Oncology. 2: S660. DOI: 10.1097/01.JTO.0000283929.23248.91 |
0.358 |
|
| 2007 |
Huang Y, Wu Y, Xie S, Yang J, Huang Y, Lioa R. P2-183: Gemcitabine weekly as a radiosensitiser for the treatment of brain metastases in patients with non-small cell lung cancer: a phase I study Journal of Thoracic Oncology. 2: S642. DOI: 10.1097/01.JTO.0000283841.31030.0F |
0.319 |
|
| 2007 |
Xu C, Guo A, Zhou Q, Dong S, Zhu J, Lin J, Yang J, Wu Y. P2-053: Establishment, identification and examination about the EGFR status of the lung cancer cell line Journal of Thoracic Oncology. 2: S511. DOI: 10.1097/01.JTO.0000283517.22290.20 |
0.351 |
|
| 2007 |
Park K, Lee J, Wu Y, Zhang L, Cheng A, Siu-Kie-Au J, Voravud N, Muthalib A, Wahid MIA, Yang C. PD3-2-6: Interim safety results from the East/South East (E/SE) Asian subgroup of the open-label TRUST (TaRceva lUng cancer Survival Treatment) study of erlotinib for advanced non-small-cell lung cancer (NSCLC) Journal of Thoracic Oncology. 2: S464-S465. DOI: 10.1097/01.Jto.0000283408.85001.F3 |
0.349 |
|
| 2007 |
Douillard J, Kim E, Hirsh V, Mok T, Socinski M, Gervais R, Wu Y, Li L, Sellers M, Lowe E. PRS-02: Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST) Journal of Thoracic Oncology. 2. DOI: 10.1097/01.Jto.0000283087.71346.19 |
0.365 |
|
| 2007 |
HUANG Y, WU Y, XIE S, YANG J, HUANG Y, LIAO R. Weekly gemcitabine as a radiosensitiser for the treatment of brain metastases in patients with non-small cell lung cancer: phase I trial Chinese Medical Journal. 120: 458-462. DOI: 10.1097/00029330-200703020-00004 |
0.318 |
|
| 2006 |
Tai AL, Sham JS, Xie D, Fang Y, Wu YL, Hu L, Deng W, Tsao GS, Qiao GB, Cheung AL, Guan XY. Co-overexpression of fibroblast growth factor 3 and epidermal growth factor receptor is correlated with the development of nonsmall cell lung carcinoma. Cancer. 106: 146-55. PMID 16329133 DOI: 10.1002/cncr.21581 |
0.308 |
|
| 2005 |
Wu Y, Lin J, Wang K, Xu C, Zhou Q, Chen G, Yang X, Yang J, Huang Y, Liao R, Huang S. EGFR mutations in lung cancers and sensitivity to gefitinib in Chinese. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7089. PMID 27944543 DOI: 10.1200/jco.2005.23.16_suppl.7089 |
0.35 |
|
| 2005 |
Wu YL, Yang X, Ren Z, McDonnell DP, Norris JD, Willson TM, Greene GL. Structural basis for an unexpected mode of SERM-Mediated ER antagonism Molecular Cell. 18: 413-424. PMID 15893725 DOI: 10.1016/J.Molcel.2005.04.014 |
0.355 |
|
| 2005 |
Wu Y, Lin J, Wang K, Xu C, Zhou Q, Chen G, Yang X, Yang J, Liao R, Huang Y. PD-161 Chinese EGFR mutation characteristics and sensitivity togefitinib in lung cancer patients Lung Cancer. 49: S113. DOI: 10.1016/S0169-5002(05)80494-5 |
0.321 |
|
| 2005 |
Yang X, Wu Y, Chen G, Xu L, Gu L, Tang P, Zhu Y, Xiao P, Tang J, Xie L. PD-102 Randomized clinical trial of adjuvant chemotherapy with docetaxel and carboplatin for completely resected stage IB to IIIA non-small cell lung cancer (NSCLC): Preliminary result of Chinese society of lung cancer (CSLC) protocol 0201 Lung Cancer. 49: S97. DOI: 10.1016/S0169-5002(05)80435-0 |
0.346 |
|
| Show low-probability matches. |